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While it has been known for almost a century that energy metabolism in cancer cells is 
dysfunctional, only recently has the importance of metabolism in cancer come to be more 
generally recognized. Dysfunctional metabolism is now acknowledged as a hallmark of cancer, 
and recently, further examples of altered metabolism in cancer cells have been demonstrated. 
Despite some targeted study of metabolism in cancer, its systems-level dynamics remain 
relatively unexplored, and a deeper understanding of these metabolic behaviors could profoundly 
affect the way that cancer is understood or even treated. Cancer stem cells are stem-like cancer 
cells that have been identified within tumors and are also poorly understood. Cancer stem cells 
are a major concern for effective cancer treatment: they have self-renewal capabilities, can 
differentiate into cancer cells, and exhibit chemo- and radioresistance; they are thus suspected as 
a primary cause of cancer recurrence. The purpose of this thesis was to characterize cancer 
metabolism in vitro using epithelial ovarian cancer as a model on an untargeted, systems-level, 
basis with particular attention paid to the difference between cancer stem cell metabolism and 
cancer cell metabolism.  
Gene expression analysis of ovarian cancer stem cells and ovarian cancer cells previously 
identified several metabolic pathways that were significantly enriched in differentially expressed 
genes between cancer stem cells and their parental isogenic cell line. To determine if there were 
substantial metabolic changes corresponding with these transcriptional differences, two-
dimensional gas chromatography coupled to mass spectrometry was used to measure the 
metabolite profiles of the ovarian cancer and cancer stem cell lines (Chapter 2). These two cell 
lines exhibited significant metabolic differences in both intracellular and extracellular metabolite 
measurements. Pathway analysis of intracellular metabolomics data revealed close overlap with 
 
 xviii 
metabolic pathways identified from gene expression data, with four out of six pathways found to 
be enriched in gene-level analysis also enriched in metabolite-level analysis. One of the most 
significantly enriched pathways, arginine and proline metabolism, contains multiple metabolites 
that are each statistically significantly different between the two cells. Two of those metabolites, 
proline and putrescine, have been previously implicated in cancer, but the changes displayed 
between normal and cancer cells are discordant with the changes they display between cancer 
cells and cancer stem cells. This behavior can be explained in the context of current research in 
stem cell metabolism, suggesting that ovarian cancer stem cells may exist in a metabolic balance 
between potency and proliferation. Overall, metabolism in this ovarian cancer stem cell line is 
distinct from that of more differentiated isogenic cancer cells, showing similarities to stem cell 
metabolism that suggest the potential importance of metabolism for the cancer stem cell 
phenotype. 
The in vitro cell culture conditions for this initial work, though, differ drastically from in vivo 
tumor conditions. To capture the metabolic profiles that would be more likely in a tumor in vivo, 
biologically-based perturbations were applied to the ovarian cancer cell and cancer stem cell 
grown in vitro (Chapter 3). Glucose deprivation, hypoxia, and ischemia are all conditions that 
occur naturally in tumors; they all perturbed ovarian cancer and cancer stem cell metabolism, but 
not in the same ways between the cell types. Hypoxia had a much larger effect on ovarian cancer 
cell metabolism, while glucose deprivation had a greater effect on ovarian cancer stem cell 
metabolism. Chemotherapeutics treatment with docetaxel caused metabolic changes mostly in 
amino acid and carbohydrate metabolism in ovarian cancer cells, though the most significantly 
altered metabolite was uracil. Ovarian cancer stem cell metabolism was not affected by 
 
 xix 
docetaxel. These differences will deepen our understanding of the metabolic changes occurring 
within the in vivo tumor.  
To expand the model system of cancer metabolism to be even more representative of in vivo 
conditions, metabolic profiles were taken of an in vitro model of the epithelial-mesenchymal 
transition (EMT), a well-known process in embryonic development now believed to take part in 
tumor metastasis and the origin of cancer stem cells (Chapter 4). Metabolic samples were taken 
over a mesenchymal to epithelial transition (MET) and a subsequent EMT. During the two 
phenotypic changes, no corresponding metabolomic changes were detected, suggesting that 
EMT/MET does not perturb cellular metabolism.  
This work explores the metabolic differences between an ovarian cancer cell line and its isogenic 
cancer stem cell line under various conditions, providing the first-ever characterization of 
ovarian cancer stem cell metabolism. This systems-level characterization of cancer metabolism 
may ultimately be key in the development of chemotherapeutics that target metabolic pathways; 





Chapter 1 Background and introduction 
Portions of this chapter are reproduced under license from our published review, Applications of 
metabolomics in cancer research, in the Journal of Carcinogenesis.1 
1.1. Cancer & cancer stem cells 
Cancer is the second leading cause of death in the United States, accounting for 25% of total 
deaths.2 In recent years, it has even overtaken heart disease related deaths in those younger than 
80.2 Ovarian cancer was the fifth leading cause of cancer-related deaths in American women in 
2010.3 Worldwide, ovarian cancer was newly diagnosed in 226,000 females and was responsible 
for 140,000 deaths in 2008.4 Ovarian cancer targets mostly women over 50 and is the most fatal 
gynecological cancer, mainly because 70% of the cases detected are at an advanced stage, when 
five-year survival rates are 30%.2, 5 Epithelial ovarian cancer is the most prevalent form of 
ovarian cancer, accounting for around 90% of cases.6  
Cancer cells (CCs) differ from normal cells by a number of distinguishable hallmarks that were 
enumerated by Hanahan and Weinberg in 2000.7 The most well-known of these six hallmarks are 
CCs’ ability to proliferate uncontrollably and invade nearby tissues or distant tissues through 
metastasis.8 Others include inactivation or evasion of growth suppressors, mutation into 
immortal cells that can replicate indefinitely, inducement of angiogenesis, and evasion of 
apoptotic as well as autophagic signaling pathways.7 Continuing research has prompted the 
addition of four new hallmarks of cancer: genomic instability, an ability to harness the immune 
system’s tumor-promoting potential and inactivate its destructive abilities, and an altered 
metabolism in order to enhance growth rate and evade destruction.9 It is the altered metabolism 
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of cancer that is the focus of this thesis; further details on cancer metabolism will be discussed in 
section 1.2.  
CCs within tumors display differing levels of differentiation and proliferation capabilities.10, 11 A 
number of theories exist to explain the heterogeneity of CCs within a tumor, including the 
stochastic model and cancer stem cell model. The stochastic model, illustrated in Figure 1.1b, 
postulates that any cancerous cell has the potential to form a tumor. A mutation (which has an 
equal chance of happening in any cancerous cell) is required to give normal cancerous cells the 
potential to populate the heterogeneous cells within a tumor To become a tumor-forming cell, a 
cancerous cell undergoes a mutation that has an equal chance of happening in any cancerous cell. 
The cancer stem cell model, shown in Figure 1.1c, is arranged in a hierarchy with the top tier 
formed by cancer stem cells (CSCs). CSCs have the potential for self-renewal and differentiation 
into the heterogeneous cells that form the tumor.10, 12 CSCs may arise from mutations of different 
cells: normal stem cells, progenitor cells, or differentiated cells with the ability to self-renew.10, 12 
After the CSCs, varying degrees of differentiated cells fill the next level and fully differentiated 
CCs lie at the bottom of the hierarchy.12 The main difference between these two models is that in 
the stochastic model, every cell has the potential to form a tumor through a mutation, while in 
the cancer stem cell model, only the CSCs have the potential to form a tumor. 
When these models were initially created, most people believed that only one model could be 
correct. Now, researchers believe that tumor heterogeneity actually occurs through a mixture of 
these two models.10, 11, 13, 14 In this combined model, shown in Figure 1.1d, CSCs are the only 
cancerous cells with the potential of forming a tumor, but the CSC state is not static. Instead, 
CSCs can transition to a differentiated state and other cancerous cells can transition to CSC state 




Figure 1.1: Tumor heterogeneity is more plastic than originally modeled. a) Typical stem cell 
hierarchy with stem cells at the top, followed by progenitor cells, and finally, fully differentiated, mature 
cells. b) Stochastic model (or clonal modal) where every cell has an equal chance of forming a tumor. 
Mutations (lightning bolts) can give cancerous cells the ability to form a tumor, as shown in the yellow 
and green transformed cells. c) The cancer stem cell follows closely the normal stem cell hierarchy, where 
only the CSCs have the ability to form a tumor. Each CSC (pink cells) has the potential for asymmetric 
and symmetric replication as well as the potential to form a tumor. d) The combined model of tumor 
heterogeneity has aspects of both the stochastic and cancer stem cell modal. Here, only CSCs (CSC1; 
pink) have the ability to form a tumor, but mutations can generate new CSCs (CSC2; blue), which also 
have tumor forming potential. Reprinted by permission from Macmillan Publishers Ltd: [Nat. Rev. 
Cancer] Visvader, J.E. & Lindeman, G.J, 200810, copyright (2008). 
Original evidence for CSCs came from isolation of cells from hematological malignancies and 
transplantation into animal models.12, 15, 16 The first evidence for solid tumor CSCs was found in 
breast cancer.10, 17 Tumor cells were isolated from human breast cancer tumors and pleural 
effusions and sorted based on cell surface markers. Only one group of CCs (a small fraction of 
the total number of cells) was able to completely reconstitute the original tumor upon 
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transplantation. These cells were labeled as CSCs. CCs that did not have the CSC markers were 
not able to reconstitute the original tumor, even when using 100 times the amount of CSCs used 
to form the tumor. Currently, CSCs are isolated and identified by their cell surface markers, but 
the lack of unique surface markers solely marking CSCs is proving problematic for complete 
isolation.18 Nonetheless, CSCs have been isolated from numerous cancers,19 including ovarian 
cancer.6, 20-23 
Recently, a link has been found between CSCs and epithelial-mesenchymal transition (EMT).24, 
25 EMT is a normal event during embryonic development, where epithelial cells are induced into 
a mesenchymal phenotype in order to develop more advanced structures and functions.26 
Epithelial cells have strong cell-cell adhesion through multiple types of junctions, which makes 
them tightly packed and immobile. Mesenchymal cells do not form junctions; instead, they have 
migratory and invasive properties. CCs have hijacked the EMT, albeit incompletely, resulting in 
further tumor progression and induction of metastasis. Normal CCs undergoing EMT have been 
shown to acquire CSC-like behavior,24, 25 as shown in Figure 1.2. During EMT, normal CCs 
obtain some stem cell-like properties, including self-renewal capabilities. By acquiring CSC-like 
behavior, these newly metastatic cells become perfectly situated to form a new tumor as CSCs 




Figure 1.2: Tumor CSCs can be induced by EMT. Intrinsic CSCs are formed from mutations in stem 
cells, progenitor cells, or differentiated cells that have gained self-renewal powers. EMT-induced CSCs 
are caused by signals from the reactive stroma that induce the CCs to undergo EMT. The EMT forms 
mesenchymal cells with CSC properties. From Chaffer et al, 201127. Reprinted with permission from 
AAAS.  
CSCs pose a major problem for cancer treatments, as they exhibit resistance to traditional 
chemotherapeutics.10, 19, 28 CSCs are believed to be able to resist chemotherapy through several 
approaches, including ATP (adenosine triphosphate)-binding cassette (ABC) drug pumps that 
expel chemotherapeutics from the cell,29 entrance into quiescence which grants resistance to 
toxins targeting fast replicating cells, and resistance to apoptosis.19, 28 Since CSCs are 
chemotherapeutic resistant and have the ability to recapitulate a new tumor, CSCs are believed to 
be a major cause of cancer recurrence. A significant challenge in ovarian cancer treatment is the 
fact that most patients die of its recurrence, after initial treatment.5 Ovarian cancer stem cells 
(OCSCs) have not only been shown to be resistant to traditional chemotherapeutics, but have 
proliferated in the presence of chemotherapy, leading to the necessity of OCSC-targeted 
therapeutics.30, 31 One area of research that could lead to therapeutic targets is the study of CSC 
metabolism and how it differs from CC metabolism. 
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1.2. Cancer metabolism 
Broadly defined, metabolism is the set of processes catalyzing the production of energy and 
cellular building blocks (amino acids, nucleotides, lipids, etc.) from the nutrients a cell takes up 
from the environment. These building blocks, and the biochemical intermediates generated 
during their production and utilization, are collectively referred to as metabolites. Metabolite 
levels integrate the effects of gene regulation, post-transcriptional regulation, pathway 
interactions, and environmental perturbations; this downstream synthesis of diverse signals 
ultimately makes metabolites direct molecular readouts of cell status that reflect a meaningful 
physiological phenotype.32-35 Therefore, it is not surprising that metabolism is altered in cancer 
since there are many other alterations in cancer cells that would be reflected in metabolism. One 
major question stems from this, though; does the altered metabolism merely reflect the cancer 
state or does the altered metabolism additionally contribute to and sustain the cancer state? 
1.2.1. Warburg effect and supporting mutations 
Though reprogramming of energy metabolism was only recently recognized as an emerging 
hallmark of cancer,9 altered cancer metabolism was first identified almost a century ago when 
Warburg discovered that cancer cells primarily use anaerobic glycolysis to produce their energy 
instead of oxidative phosphorylation, even in the presence of oxygen – a phenomenon known as 
the Warburg effect or aerobic glycolysis.36, 37  
Over the years, many common cancer mutations have been shown to support the Warburg 
effect.38 AKT1, HIF, and p53 together cause increased flux of glucose through glycolysis and 
down-regulation of flux through the tricarboxylic acid (TCA) cycle (Figure 1.3), thereby 
supporting the Warburg effect and carcinogenesis.39-47 AKT1 is a downstream effector in the 
PI3K pathway, which is up-regulated in cancer. AKT1 administers growth and survival signaling 
and has a strong effect on metabolism27: it stimulates glycolysis through phosphorylation of 
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glycolytic enzymes and transcriptional up-regulation of glucose transporters.39 Hypoxia-
inducible factor 1 (HIF1), whose induction is caused by the highly hypoxic conditions present in 
tumors, induces the Warburg effect by increasing glycolytic transport and expression of 
enzymatic genes while down-regulating the TCA cycle, a critical pathway that feeds electrons to 
oxidative phosphorylation.40 HIF1 decreases TCA cycle flux via pyruvate dehydrogenase41-43, 
the enzyme linking glycolysis and the TCA cycle. p53, a commonly down-regulated gene in 
cancer, has several regulatory functions that control metabolism38. Although p53 promotes 
expression of hexokinase (the first enzyme in glycolysis),44 it also stimulates oxidative 
phosphorylation,45 induces the expression of TP53-induced glycolysis and apoptosis regulator 
(TIGAR) (an enzyme that down-regulates glycolysis),46 and down-regulates phosphoglycerate 
mutase (PGAM1) (a glycolytic enzyme)47. Therefore, even though p53 normally promotes 
hexokinase, overall, the down-regulation of p53 in cancer still supports the Warburg effect. 
Loss-of-function mutations of mitochondrial enzymes succinate dehydrogenase (SDH) and 
fumarate hydratase (FH) also support the Warburg effect.48 The mutations of these two tumor 
suppressors allow for build-up of succinate and fumarate in the mitochondria, leading to their 
eventual escape. These metabolites have been shown to inhibit prolyl hydroxylases (PHDs) – a 
family of enzymes that participate in multiple pathways, one of which is to tag HIF for 
degradation.48-51 Therefore, accumulation of succinate and fumarate support HIF accumulation, 
which leads to increased glucose transfer into the cell and suppression of the TCA cycle, as 
discussed above. 
Pyruvate kinase (PK) is another commonly altered enzyme in cancer with metabolic implications 
(Figure 1.3). PK converts phosphoenolpyruvate (PEP) into pyruvate and is a rate-limiting step in 
glycolysis. There are four human isoforms of PK: L, R, M1 and M2. L and R are limited to a few 
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specific cell types. M1 is expressed in most adult cells, and M2 is expressed in self-renewing 
cells, like embryonic stem cells.52 PKM2 is less active than PKM1, is activated allosterically by 
fructose-1,6-bisphosphate (FBP), and is negatively regulated through tyrosine kinase signaling in 
CCs. 53, 54 Expression of less-active, rate-limiting PKM2 leads to a smaller flux of its catalyzed 
reaction and an accumulation of upstream glycolytic intermediates.38 Interestingly, most CCs 
express the isoform PKM2, switching over from PKM1 expression during carcinogenesis. 
Research into PKM2’s effect on cancer has shown that CCs expressing PKM2 consume less 
oxygen and produce more lactate than the same CCs expressing PKM1, suggesting a significant 
role in the manifestation of the Warburg effect.55 Lung CCs expressing PKM2 in vivo showed 
faster tumor development, a greater number of tumors, and larger tumors than the same cells 
expressing PKM1.55 
Expression of PKM2 in most cancer cells causes the rate-limiting step of glycolysis to become 
even slower, which would normally result in accumulation of glycolytic intermediates and the 
natural down-regulation of glycolysis. However in cancer cells, glycolytic intermediates are 
rerouted down one of the many pathways that branch off from glycolysis. One of the most 
notable of these pathways is the pentose phosphate pathway (PPP), which produces NADPH 
(nicotinamide adenine dinucleotide phosphate, reduced) and ribose-5-phosphate, both important 
reagents for biosynthetic pathways required for proliferation. It has been discovered that p53, 
discussed above as a regulator of many metabolic pathways, also controls flux into the PPP via 
control of glucose-6-phosphate dehydrogenase (G6PD), which catalyzes the rate-limiting 
reaction between glycolysis and the PPP.56 In normally functioning cells, cytoplasmic p53 
inhibits G6PD and thus limits metabolic flux through the PPP.56 Since p53 is inactivated in most 
tumors, cytosolic p53 is not present to inhibit G6PD in CCs, increasing the flux into the PPP and 
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increasing production of NADPH and ribose-5-phosphate.56 These metabolites are then used by 
the highly proliferative cells. 
 
Figure 1.3. Illustration of important relationships between metabolome, proteome, and genome in 
cancerous cells. Glycolysis breaks down glucose into pyruvate, which is then fermented to lactate; 
pyruvate flux through the TCA cycle is down-regulated in cancer cells. Pathways branching off of 
glycolysis (such as the PPP) generate biochemical building blocks to sustain the high proliferative rate of 
cancer cells. Specific genetic and enzyme-level behaviors are described in the main text. Blue boxes are 
enzymes important in transitioning to a cancer metabolic phenotype; orange boxes are enzymes that are 
mutated in cancer cells. Green ovals are oncogenes that are up-regulated in cancer; red ovals are tumor 
suppressors that are down-regulated in cancer. Abbreviations are as defined in the abbreviations section. 
Figure from Vermeersch, et al, 2013.1 
Even with most CCs expressing less-active PKM2 over PKM1, they still produce abnormally 
high levels of lactic acid. This increase in lactic acid production suggests the possible existence 
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of another path from PEP to pyruvate, as pyruvate fermentation produces lactic acid. An 
alternative pathway has been found, shown in Figure 1.3, that converts PEP to pyruvate through 
the phosphorylation of the glycolytic enzyme phosphoglycerate mutase 1 (PGAM1).57 PEP has 
been shown to directly phosphorylate PGAM1 without requiring enolase conversion of PEP to 2-
phosphoglycerate.57 The phosphorylation reaction produces pyruvate without producing ATP, 
allowing pyruvate production to be decoupled from energy generation and the low activity of 
PKM2.57 By decoupling energy generation from glycolysis, pyruvate production from PEP can 
continue, regardless of ATP regulation or dependence on PKM2. This continuous pyruvate 
production accounts for the high levels of lactic acid characteristic of CCs.  
A consequence of the Warburg effect is an elevated amount of lactic acid production, which is 
expelled by the CCs into their environment.37 The lactic acid and CO2 (generated by the PPP) 
produced is enough to lower the extracellular pH from 7.4 (physiological pH) to below 6.5 in 
some tumor locations.58 This acidic environment helps cancer cells to decrease sensitivity to 
hypoxia, stimulate metastasis, and increase drug resistance.59, 60 Recent research indicates that 
lactate might help suppress immune response to the tumor, as well as induce chronic 
inflammation in the tumor site.61 Overall, the acidic environment of the tumor helps maintain and 
further tumorigenic potential. 
1.2.2. Glutaminolysis 
Along with aerobic glycolysis, another pathway discovered to have increased flux in cancer cells 
is glutaminolysis.62 Glutaminolysis is a catabolic pathway that converts glutamine to lactate, 
producing NADPH. By increasing the flux through glutaminolysis, cancer cells are able to 
produce an abundance of NADPH, completely covering the needs of fatty acid biosynthesis.62 
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Glutamine has also been shown to play an important role in cancer metabolism by serving as an 
anaplerotic precursor to oxaloacetate (OAA), a TCA intermediate.62  
c-Myc, a protein produced by the oncogene MYC, interacts with HIF to regulate several 
enzymes involved in glucose metabolism, shown in Figure 1.3, but has also recently been shown 
to play a role in glutaminolysis.63, 64 Mitochondrial glutaminase (GLS) expression correlated with 
Myc expression in several different cell lines, including a human prostate cancer cell line.64 GLS 
is a mitochondrial enzyme that converts glutamine to glutamate, the first step in the anaplerotic 
conversion of glutamine to OAA. Through characterization of the relationship between GLS and 
Myc expression, it was discovered that Myc indirectly regulates GLS through two microRNAs, 
miR-23a and miR-23b.64 miR-23a/b target the 3’ UTR of GLS and inhibit GLS expression. Myc 
alleviates miR-23a/b inhibition by transcriptionally repressing these two microRNAs, which in 
turn allows for increased GLS expression. The effect of Myc upon the conversion of glutamine 
to proline has also been studied. It was shown that Myc stimulates proline production by 
suppressing proline oxidase, also known as proline dehydrogenase (POX/PRODH), through 
miR-23b*64, 65 (miR-23b & miR-23b* are processed from the same transcript). POX/PRODH is 
an enzyme involved in the first step of proline catabolism. This enzyme has been shown to act 
like a tumor suppressor66-69 - when proline is metabolized to glutamine, electrons are produced 
and in turn produce ROS, which eventually leads to apoptosis. It is not yet known why proline 
production is stimulated through conversion of glutamine. 
The effect of GLS suppression on glutamine-dependent tumor cells has also been studied. Tumor 
cells are able to use glucose sources to compensate for the lack of glutamine using the enzyme 
pyruvate carboxylase.70 In some glutamine-independent cancer cell lines in which GLS 
suppression had no effect, pyruvate carboxylase was also found to be active. During 
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gluconeogenesis, pyruvate carboxylase is responsible for producing oxaloacetate. The 
mechanism of pyruvate carboxylase induction is not yet known, but it is believed to be 
complex.70 Pyruvate carboxylase may allow glutamine-dependent cancer cells a pathway for 
resistance against glutamine-targeted therapies. 
1.2.3. Altered Metabolism: Byproduct or Condition of Cancer? 
Cancer metabolism is clearly different from normal cellular metabolism, but it has still not been 
conclusively determined if this alteration is a byproduct or a necessary condition of cancer. 
Originally, Warburg postulated his effect as a condition of cancer, and not as a product of the 
cells being cancerous.37 Recently, experimental evidence has been offered in favor of the 
metabolism shift being a determinant of cancer. As mentioned above, when CCs were forced to 
express PKM1 over PKM2 in vivo, decreased tumor growth and development rate were seen. 
PKM1 expression was shown to favor oxidative phosphorylation over glycolysis, showing that 
CCs not partaking in the Warburg effect were at a proliferative disadvantage to those that did. 
Further experimental support has been provided by a dicholoroacetate-activated shift from 
glycolysis to oxidative phosphorylation in CCs causing a decreased growth rate and apoptotic 
sensitivity in the CCs, two cancer hallmarks.71 The fact that this metabolic alteration has the 
capability to cause CCs to lose defining hallmarks suggests that cancer metabolism is a necessary 
condition of cancer rather than just a byproduct. 
Further evidence of metabolism assisting in the carcinogenic transition comes from the 
additional regulatory roles that metabolites play in controlling proliferation. For example, some 
metabolites can also serve as signaling molecules. Diacylglycerol, a lipid that plays a structural 
role in membranes, acts as a second messenger in mammalian cells; deregulation of 
diacylglycerol can lead to cancer progression through activation of protein kinase C, a family of 
 
 13 
kinases that regulate cellular process such as proliferation and apoptosis.72 Arginine, a metabolite 
involved in many anabolic pathways, plays a role as a signaling molecule in angiogenesis, tumor 
development, and apoptosis.73 Along with having roles as signaling molecules, metabolites can 
also directly control gene expression in three different ways: they can bind to regulatory regions 
of mRNAs, activate transcription factors upon binding, and take part in epigenetic regulation 
such as post-transcriptional modification of histones.73 Since metabolism assists in the transition 
to a cancerous state and affects many pathways through signaling and control of gene expression, 
it serves as a potential target for cancer therapeutics.74, 75 
1.2.4. Cancer stem cell metabolism 
Though study of CSC metabolism is an emerging field, there are suggestions that CSC 
metabolism would differ from CC metabolism. CSCs exist in a state of quiescence, and therefore 
their metabolic demands are probably quite different from the fast-growing state of CCs. Along 
with this, one of the assays used to separate CSCs from CCs is based on the enzymatic activity of 
aldehyde dehydrogenase (ALDH).76ALDH activity is higher in CSCs and is thought to be 
connected to their chemoresistance.77 Intriguingly, ALDH activity is higher in quiescent CSCs, 
suggesting that this difference is not merely an artifact of a slower metabolic rate of CSCs 
compared to CCs, which indicates that both enzymes and metabolite levels in pathways 
associated with ALDH could also differ to some extent between these two cells.  
As previously described, one of the most well-known metabolic alterations in cancer is the 
Warburg effect. In an effort to determine if CSCs utilize anaerobic glycolysis to the same extent 
CCs do, one group looked at glycolysis utilization in glioma and glioma stem cells (GSCs).78 
They discovered that GSCs have much lower glycolysis activity than glioma cells and mainly 
use oxidative phosphorylation for most of their ATP generation, although GSCs were still able to 
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switch freely between the two energy-generating pathways. They theorized that glioma cells 
switch to anaerobic glycolysis during differentiation from GSCs. Interestingly, another group has 
looked at CSCs in glioblastomas and has found the exact opposite holds true for these CSCs; 
they have high flux through glycolysis and use this pathway for most of their energy 
generation.79 Based on these observations, it is possible that different CSC populations could 
have unique metabolic profiles that vary between different cell types. 
Even though there has been some preliminary research done on CSC metabolism, most of it has 
been extremely focused on glycolysis and the Warburg effect. Only one study has been done that 
looks at system-wide metabolic differences between CCs and CSCs, and that study focused more 
on the metabolic differences between freshly derived CSCs and cultured CSCs and the tumors 
formed from these cells.80 With a better understanding of systems-level metabolic differences 
between CSCs and CCs, we would better understand how CSCs function and therefore be better 
prepared to isolate and treat these cells. 
1.3. Metabolomics and cancer 
Metabolomics is the emerging field focused on comprehensive profiling of metabolites in a 
sample, whether intracellular or from circulating biofluids. The ability of metabolomics to 
measure high-throughput, system-wide phenotypes gives it great power in the field of oncology 
to further characterize what is happening in cancer cells.  
1.3.1. Metabolomics analytical technology 
Metabolites are very chemically diverse; they range from non-polar, long chain lipids to polar, 
small amino acids. Due to this vast chemical diversity, no single analytical method can measure 
at once all possible metabolites. Therefore, researches will either confine themselves to a smaller 
range of metabolites or combine multiple metabolomics technologies to cover a wider range. The 
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two dominant metabolomics technologies are nuclear magnetic resonance (NMR) spectroscopy 
and mass spectrometry (MS) coupled to a separation technique. Both of these technologies and 
the roles they play in metabolomics are extensively detailed elsewhere,81-83 but a brief 
description will be given here.  
1.3.1.1. Nuclear Magnetic Resonance 
NMR spectroscopy provides quantitative and structural information and can measure a wide 
range of metabolites with little to no sample preparation. Techniques including high resolution 
NMR (HR-NMR) spectroscopy and high resolution magic angle spinning NMR (HR-MAS-
NMR) spectroscopy have been used to profile cancer metabolism in biofluids as well as tissue 
samples, and are particularly valuable since they do not destroy samples, allowing for parallel 
analysis with other techniques.84, 85 Another emerging technology, hyperpolarized NMR 
spectroscopy, has been used to characterize cancer metabolism by tracing metabolite levels in 
vivo86, with potential applications in clinical diagnosis or treatment of cancer.87 One limitation of 
NMR spectroscopy, though, is its low sensitivity and thus higher limits of detection for 
metabolites. Additionally, in complex mixtures the interpretability of NMR spectra and 
association with specific metabolite identities can be difficult.  
1.3.1.2. Mass Spectrometry 
MS provides semi-quantitative information with very high sensitivity, allowing the analysis of 
low-abundance metabolites. MS-based analyses can be broadly divided into direct injection 
techniques – including direct infusion mass spectrometry (DIMS)88 and direct analysis in real 
time (DART-MS)89 – and separation-coupled techniques, including gas chromatography (GC-
MS), liquid chromatography (LC-MS), and capillary electrophoresis (CE-MS). Common types 
of mass spectrometers include time-of-flight (TOF), quadrupole time-of-flight (QTOF), 
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quadrupole, and orbitrap. Separation methods and MS can also be combined in series (GCxGC-
MS or LC-MS/MS) to gain better separation or more structural information. However, many 
MS-based techniques require extensive sample preparation and usually can only measure 
specific subsets of metabolites. 
1.3.1.3. Data Handling, Processing, and Analysis 
The complex raw data captured by metabolomics instruments must first be converted into 
human-interpretable measurements; the resulting vast datasets then require significant analysis 
and interpretation. Numerous data processing techniques and packages have been created for all 
steps of this data-processing pipeline.90 Packages vary depending on the technology used to 
generate the data set and the goal of the processing. For example, packages aimed at specific 
technologies (XCMS for LC-MS)91 will have different metabolite identification methods than 
packages aimed at another technology (ChromaTOF for GC-TOF-MS). Even though packages 
differ, most processing pipelines follow a similar trend (but not necessarily in this order): 
quantification of analyte levels in some way, identification of analytes, and finally alignment of 
analytes across multiple samples. Analysis of these processed metabolomic data sets can involve 
several different techniques, many of which can be categorized as univariate or multivariate 
analysis.92 Univariate analyses only assess one variable at a time; common examples include fold 
change calculations and statistical hypothesis testing (t-test, ANOVA) with false discovery rate 
correction. Multivariate analyses takes into account two or more variables and include 
correlations, principal components analysis (PCA), partial least squares discriminant analysis 
(PLS-DA), and set/pathway enrichment analysis. Both uni- and multivariate approaches are 
usually used for analysis of metabolomics data sets, in order to capture metabolite variation on 
both an individual and a systems-scale level. 
 
 17 
1.3.2. Metabolomics-based discoveries of altered cancer metabolism 
The system-wide analyses of metabolomics allow a unique opportunity for the study of cancer 
biology by enabling deep investigation of targeted aspects of cancer metabolism while also 
allowing discovery-based analysis of metabolism writ large.  
For example, NADP+-dependent isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) are 
commonly subject to gain-of-function point mutations in gliomas.93 Using metabolomics, it was 
discovered that mutated IDH1 and IDH2 catalyze (R)-2-hydroxyglutarate (2HG), a rare 
metabolite, from α-ketoglutarate (α-KG) (Figure 1.3).94 2HG has been referred to as an 
oncometabolite, as its production helps to further the cancer phenotype.94, 95 Metabolic profiling 
on glioma cells using LC-MS/MS and GC-MS showed that IDH1/2 mutations caused N-
acetylated amino acid and TCA cycle intermediate levels to drop and biosynthetic molecules to 
accumulate, while not affecting glycolytic intermediates.96 The effects of IDH1/2 mutations on 
the metabolome were very similar to the changes caused by treating normal cells with 2HG, 
showing that it is production of the oncometabolite 2HG and not the loss of IDH1/2’s normal 
function that causes these changes.96  
Another (though somewhat disputed97) example of mechanistic insight from metabolomics is in 
sarcosine’s putative role in prostate cancer progression. Samples from patients with benign, 
localized and metastatic prostate cancer were profiled using both LC-MS and GC-MS. From this 
metabolic profiling, sarcosine levels were identified as increasing from benign to metastatic 
prostate cancer. In vitro, sarcosine levels were shown to directly correlate to a cell’s level of 
invasiveness. Further investigation showed that sarcosine is regulated by an androgen receptor 
and ETS gene fusions through transcriptional control of its regulatory enzymes.98  
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A final example of metabolomics-based mechanistic insight is the recent study of extracellular 
metabolite profiles across the NCI-60 cancer cell lines.99 Glycine consumption was found to be 
correlated with proliferation rate in cancerous cells, but not in proliferative non-cancerous cells, 
suggesting cancer-specific behavior. De novo purine nucleotide biosynthesis was one pathway 
involved in the increased glycine consumption. Follow-up analysis of breast cancer gene 
expression data revealed that glycine mitochondrial enzyme expression correlated with cancer 
mortality.  
1.3.3. Biomarkers and diagnosis 
A central focus in cancer metabolomics research is biomarker discovery. Metabolites are 
reasonable biomarkers and diagnostics, as they can be easily measured from noninvasive urine or 
blood samples. Many groups are attempting to use metabolic profiles as biomarkers or diagnostic 
tools since levels of multiple metabolites can provide better classification than a single entity. 
For example, the diagnostic capability of a set of 113 cis-diol structured urinary metabolites for 
liver cancer resulted in a lower false-positive rate than the traditional tumor marker alpha-
fetoprotein when classifying liver cancer against hepatocirrhosis and chronic hepatitis 
samples.100 Essentially every type of cancer is being investigated for metabolic biomarkers and 
diagnosis, including breast,101-107 colon,108-113 kidney,114-117 liver,100, 118-124 and ovarian.  
A major focus in ovarian cancer metabolomics research has been in early detection, as the 5-year 
survival rate when caught in early stages is greater than 90%, but when diagnosed in later stages 
(as it is for most patients) is almost inverted.125, 126 A number of studies have attempted to use 
metabolomics analysis of urine or serum as an early diagnosis tool.89, 127, 128 One particularly 
promising model used DART-MS to profile the metabolome of 44 ovarian cancer patients and 50 
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healthy patients through serum samples, obtaining 99% separation accuracy using a customized 
algorithm.89 
1.3.4. Emerging applications of metabolomics in cancer research 
1.3.4.1. Metabolomics and Metastasis 
Metabolomics research has shown promising results for detection of metastasis. Metabolic 
profiles of serum or urine samples suggest predictive capabilities for diagnosing metastases 
forming from gastric cancer129, colorectal cancer 130, kidney131, 132, and breast cancer104, 105, 133. 
Other studies have focused on specific metastatic sites such as leptomeningeal carcinomatosis134 
and bone metastases135, the latter of which contain higher levels of cholesterol for prostate cancer 
metastases when compared to other cancerous bone metastases and normal bone.  
1.3.4.2. Staging of Cancer 
Beyond detection, metabolomics may also serve a role in distinguishing between different stages 
of cancer. In one study, GC-MS analysis of serum from pancreatic cancer patients was able to 
distinguish between Stage III, Stage IVa, and Stage IVb groups.136 Another study used GC-TOF-
MS to analyze ovarian cancer samples and showed metabolic distinction between ovarian 
carcinomas and borderline tumors.137 In colorectal cancer, HR-MAS-NMR profiling not only 
distinguished between tumor and adjacent mucosa samples, but also between the mucosa 
samples themselves based on the stage of their adjacent tumor.138 
1.3.4.3. Metabolomics and Treatment 
An emerging field of study for metabolomics is pharmacometabolomics – the use of 
metabolomics to predict physiological responses for drug efficacy and/or toxicity. There are 
currently few pharmacometabolomics studies in oncology, but research in the area is expected to 
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grow139, particularly since pharmacometabolomics is already achieving widespread attention in 
other fields140-146. In a pharmacometabolomic study of toxicity effects of capecitabine on 
colorectal cancer patients, lipoprotein-derived lipid levels were discovered to correlate with the 
intensity of toxicity, yielding predictive capabilities.147 In another study, metabolic profiling of 
serum before and during chemotherapy from breast cancer patients with metastasis found that 
metabolite profiles from HER-2 positive patients treated with paclitaxel and lapatinib correlated 
with overall survival and time to progression (though the correlation did not hold across the 
entire population).148 
1.4. Thesis overview 
Metabolomics holds great promise for advancing the understanding, diagnosis, and treatment of 
cancer. The approach has already been used to uncover and verify mechanisms of carcinogenesis 
and proliferation, identify numerous candidate diagnostic biomarkers in biofluid and biopsy 
samples, and even contribute to the staging of cancers and the characterization of treatment 
efficacy. However, one area metabolomics research has not been applied to is the differences 
between CC and CSC metabolism. Applying proven metabolomics techniques to CC and CSC 
metabolism will allow further understanding in an area of cancer that has been largely 
unexplored until now. 
The purpose of this thesis was to profile CC and CSC metabolism in vitro using epithelial 
ovarian cancer as a model through three different approaches: (a) studying their baseline 
metabolic differences, (b) profiling metabolic differences in response to biologically based 




1.4.1. Baseline metabolic differences between OCCs and OCSCs 
As discussed above, there are initial indications that CSC and CC metabolism differ. For 
instance, CSCs are known to proliferate at a lower rate than CCs and could have different 
metabolic requirements based purely on their proliferation rates. In order to fully understand the 
differences between these two cells, a comparison between OCCs and OCSCs during normal 
growth was made. This comparison provided baseline differences between the two cell types. 
Profiling the cells over a period of 48 hours determined how the cells change during their normal 
feeding cycle and if there are significant changes over time during normal growth. Baseline 
differences can be used to understand the different metabolic requirements of the OCSCs as 
compared to the OCCs. 
1.4.2. Metabolomic differences between OCCs and OCSCs in response to 
biologically based perturbations 
In vitro growth conditions differ drastically from growth conditions found within the tumor. In 
vitro, all cells are supplied with an overabundance of nutrients, plenty of oxygen, and their 
environment is cleaned out every two to four days to remove buildup of expelled molecules and 
to provide fresh supplies of nutrients. Tumor conditions are nowhere near as ideal or stable as in 
vitro conditions. Cells do not grown in a monolayer, therefore the cells in the middle of the 
tumor do not receive an adequate supply of nutrients or oxygen, even with angiogenesis. Overall, 
these cells are growing in conditions far from ideal, and therefore they must alter their 
metabolism to continue to proliferate and sustain the tumor. 
To mimic the harsh conditions in the in vivo tumor environment, biologically based perturbations 
were applied to the in vitro grown OCCs and OCSCs. The perturbations chosen for these 
experiments were glucose deprivation, hypoxia, ischemia, and chemotherapeutic treatment, 
which were applied over a period of 48 hours with time points taken. Profiling and comparing 
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OCC and OCSC metabolism in response to these perturbations can further understanding on how 
the two cells handle the stresses encountered in the tumor microenvironment. 
1.4.3. Metabolic changes during MET  
As discussed above, the epithelial to mesenchymal transition (EMT) occurs normally during 
embryonic development. Research into tumor metastasis has led to the belief that CCs use EMT 
to gain metastatic potential. Cells undergoing EMT have also been shown to obtain stem-like 
properties. MET is the reversal of EMT, and would mimic CCs losing stem-like properties. This 
experiment profiled the metabolism of OCCs undergoing MET – induced through microRNA 
transfection - and then the reverse EMT as the microRNA levels drop. Metabolic changes during 
differentiation-like conditions might give insight into metabolic pathways that could be targeted 
to stop the plastic transition between CSCs and CCs.  
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Chapter 2 OVCAR-3-derived ovarian cancer stem cells display 
distinct metabolic profiles 
This chapter is taken from OVCAR-3-derived ovarian cancer stem cells display distinct 
metabolic profiles, which is under review in PLOS ONE. 
2.1. Introduction 
Ovarian cancer is the most deadly gynecological cancer and the 5th leading cause of cancer-
related death in United States women. An estimated 15,500 U.S. women died from ovarian 
cancer in 2012.1 Even though response to the first-line treatment is high, most patients (50-75%) 
relapse after the treatment.2 Recently, side populations of cancer cells with ABC-transporter 
activity and ability to efflux certain compounds have been identified in many different types of 
tumors, including ovarian cancer.3-5 These cells are referred to as cancer stem cells because of 
their many unique properties: they have self-renewal and differentiation capabilities and exhibit 
resistance to the effects of radiation and anticancer drugs.6 Based on these properties, they are 
suspected as a primary cause of ovarian cancer recurrence.7, 8 
We have previously established an ovarian cancer stem cell (OCSC) line as a sub-population of a 
widely-used ovarian cancer cell (OCC) line, OVCAR-3.8 These cells were shown to demonstrate 
numerous characteristics of cancer stem cells, including self-renewal, the ability to produce 
differentiated progeny, increased expression of genes associated with cancer stem cells, higher 
invasiveness, migration potential, and enhanced chemoresistance. Transcriptional analysis 
identified changes in various signaling pathways including TGF-beta-dependent induction of 
epithelial-to-mesenchymal transition, regulation of lipid metabolism, and NOTCH and 
Hedgehog signaling. In addition, six pathways associated with metabolism were identified as 
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being enriched with genes differentially expressed between OCSCs and OCCs, suggesting a 
potential role of metabolic differences as a cause or consequence of the phenotypic differences 
between the two cell types.  
Since transcriptional changes do not always directly translate to changes in metabolism, we 
sought to directly test the prediction that OCCs and isogenic OCSCs may display significant 
differences in metabolism. Metabolomics is the systems-scale analysis of the levels of small-
molecule biochemical (metabolic) intermediates in the cell. Metabolomics is a field that is 
increasingly being brought to bear on the study of cancer, with promising results including 
insights into disease mechanisms as well as the identification of circulating biomarkers for 
potential use in diagnostics.9-12 Metabolomics has the potential to reveal key intracellular 
pathways or metabolites and their related enzymes in OCSCs that may serve as potential 
therapeutic targets, as well as secreted or intracellular metabolites that may find potential use in 
diagnostic tests. However, to date metabolomics has rarely been exploited to study cancer stem 
cells. To our knowledge, the only reported application of metabolomics in this context was its 
use to study the differences between tumors derived from fresh glioma stem cells and cultured 
glioma stem cells in vivo using nuclear magnetic resonance spectroscopy.13 
In this study, we analyzed the intracellular and extracellular metabolomic profile of both ovarian 
cancer cell types in vitro over two days using two dimensional gas chromatography-mass 
spectrometry (GCxGC-MS). Consistent with gene expression-driven predictions, we identified 
significant differences between the metabolism of these two cell types. Our findings are 
consistent with the hypothesis that metabolic changes may contribute to the functional 
differences between ovarian cancer stem cells and their more differentiated progeny that 
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represent the majority of bulk tumor tissue. More generally, our findings are consistent with the 
mounting body of evidence that altered metabolism is one of the hallmarks of cancer.14 
2.2. Results & Discussion 
2.2.1. OCCs and OCSCs have significant differences on an individual 
metabolite level 
GCxGC-MS analysis of OCCs and OCSCs detected 211 intracellular and 203 extracellular 
reproducibly measurable analytes overall, including unknowns and analytes that did not map to 
known human metabolites (based on KEGG and HMDB identifications available in 
MetaboAnalyst). Differences due purely to growth media differences were removed for the 
intracellular data set, using the medium control experiment as a basis (as described in section 
2.4.7), but could not be completely removed from the extracellular data set. Since the 
intracellular samples showed no medium-related artifacts and thus allowed for the most direct 
interpretation, moving forward we focused our attention and analysis on those data.  
Once these analytes were removed, the resulting intracellular dataset contained 177 unknown 
and known analytes, which included 40 unique and annotated metabolites. Basic univariate 
analysis of metabolite levels provided insight into the differences between the two cell types. Of 
the 40 intracellular metabolites, 27 were significantly different (t-test, all time points, false 
discovery rate (FDR) < 0.05) between the two cell types, shown in Table 2.1. Nineteen of these 
27 metabolites had a fold change greater than two. Based on these statistical differences, 
metabolism seems to be fundamentally altered in OCSCs, though it is impossible to conclude 
based on metabolite levels alone (without fluxes) whether this may be due to increased or 
decreased metabolism.  
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Table 2.1: List of intracellular metabolites statistically significant between OCCs and OCSCs and 
their fold changes. Fold changes represent the change of OCC levels with respect to OCSC levels of the 
metabolite. 
Metabolite p value FDR log2(FC) 
Gamma-Aminobutyric acid 2.75E-16 1.10E-14 2.741 
D-Psicose 4.96E-10 9.91E-09 1.997 
Erythronic acid 4.57E-08 6.10E-07 1.411 
Pyrophosphate 6.38E-08 6.38E-07 2.792 
Fumaric acid 1.04E-07 8.29E-07 1.751 
Erythritol 8.14E-07 5.43E-06 4.243 
Putrescine 4.54E-05 2.59E-04 1.739 
L-Isoleucine 6.83E-05 3.34E-04 1.187 
L-Proline 7.51E-05 3.34E-04 2.736 
L-Glutamate 8.80E-05 3.52E-04 1.107 
L-Lysine 1.68E-04 6.11E-04 -1.155 
Mannitol 2.06E-04 6.86E-04 0.702 
Cholesterol 4.01E-04 1.23E-03 0.543 
Glycerol 4.62E-04 1.25E-03 -0.754 
Pyroglutamic acid 4.69E-04 1.25E-03 0.833 
Ethanolamine 6.40E-04 1.51E-03 -0.626 
L-Aspartic acid 6.15E-04 1.51E-03 1.265 
Uridine 5'-monophosphate 1.09E-03 2.43E-03 0.675 
3,7-Dimethyl-3-octanol 2.01E-03 4.00E-03 -0.364 
Glycine 1.92E-03 4.00E-03 0.987 
L-Malic acid 2.10E-03 4.00E-03 1.611 
N-Decane 4.08E-03 7.09E-03 -0.536 
Mannose 6-phosphate 4.05E-03 7.09E-03 0.600 
Glycerol-3-phosphate 1.43E-02 2.38E-02 0.439 
Citric acid 1.62E-02 2.60E-02 -0.267 
Hydrogen sulfide 2.00E-02 3.08E-02 0.599 
Hexadecane 2.26E-02 3.34E-02 -0.586 
 
2.2.2. Metabolomic analysis reveals distinct metabolic profiles between 
OCCs and OCSCs 
Unsupervised dimensional reduction using principal components analysis (PCA) showed 
complete separation for the intracellular metabolic profiles between OCCs and OCSCs, as seen 
in Figure 2.1. PCA of intracellular annotated metabolite measurements showed that the distinct 
metabolic profiles between the two cell types were captured mostly in principal component (PC) 
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1 with the second PC providing additional separation, as seen in Figure 2.1B. In both of the 
intracellular plots, the second PC shows some separation between different time points. The fact 
that this unsupervised method was able to separate sample classes so strongly in the first few PCs 
suggests the presence of true metabolic differences that are not artifacts of data analysis. PCA 
based on the entire measured dataset (including unknowns, not just the identified human 
metabolites) yielded similar separation (Figure 2.1A), with a number of unknowns having high 
loading scores in PCs 1 and 2, suggesting that the differences between the two cell types are not 
limited to just the well-characterized sections of cellular metabolism.  
 
Figure 2.1: Principal components analysis easily distinguishes between the metabolic profiles of 
OCCs and OCSCs. Red points are OVCAR-3 cells, and green points are ovarian cancer stem cells at six 
different time points with three biological replicates at each time point. Principal component (PC) axes 
include the percentage of variation captured by each axis. A) PC 1 captures the cell type separation for the 
unknown and annotated analytes, with PC 2 capturing some time point separation. B) Including only the 
profiles of annotated metabolites shows complete cell type separation in PC 1 and some time point 
separation in PC 2. 
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Analysis of the PCA loadings revealed the metabolites that were the most important in causing 
the separation seen in the intracellular PCA plots. Fumarate, erythronic acid, psicose, 
pyrophosphate, gamma-aminobutyric acid, aspartate, isoleucine, uridine 5'-monophosphate, 
putrescine, and glutamate are most responsible for the cell type separation in the intracellular 
data set. Interestingly, putrescine, aspartate, glutamate, and fumarate are all involved in the 
arginine and proline pathway, which was identified in gene set enrichment analysis as 
significantly enriched in the OCSC phenotype (discussed in more detail below).  
Hierarchically clustered heatmaps of the intracellular metabolic profiles also revealed distinct 
patterns, shown in Figure 2.2. The samples for OCC and OCSC cluster together tightly, showing 
the similarity within each specific cell type. Two main groups of analytes are evident within the 
clustered heatmap. Group 1 metabolites have higher levels in OCCs than OCSCs across all 
samples. This group consists mostly of amino acids and carbohydrates. Again, interestingly, 
putrescine, fumarate, glutamate, aspartate, and proline (metabolites involved in the arginine and 
proline pathway discussed below) all fall within group 1 of intracellular metabolites. Group 2 
metabolites have higher levels in OCSCs and lower levels in OCCs across all samples, including 





Figure 2.2: Hierarchical clustering demonstrates clear separation between cell type and major 
trends in analyte levels. Columns represent hierarchically clustered samples, color-coded according to 
cell type. Rows represent hierarchically clustered analytes. Analyte levels are mean-centered and unit-
variance on a per-metabolite basis. The intracellular profile consists of two major groups with clearly 
separate behavior between the cell types. In group 1, OCC analyte levels are generally higher than OCSC 
analyte levels. Group 2 analyte levels are lower in OCCs than OCSCs.  
Analysis into time series trends showed smaller clusters of metabolites whose levels varied with 
time (increasing or decreasing) in one cell line but did not substantially vary in the other cell line 
(see Figure 2.3). Further analysis into the metabolites from these clustered groups show that the 
metabolites have similar trends over time, as shown in Figure 2.4. In one group (Figure 2.4A), 
metabolites from time series cluster 1 in the hierarchical clustered heatmap, all metabolites have 
higher levels in OCCs than in OCSCs and this group is enriched in amino acids and 
carbohydrates. The second group (Figure 2.4B) consists of metabolites with higher levels in 
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OCSCs than OCCs (cluster group 3 from time series ordered hierarchical clustered heatmap) and 
is enriched in aliphatic acyclic compounds and lipids. 
 
Figure 2.3: Time series ordered hierarchical clustering shows clusters of analytes with levels that 
increase or decrease with time. Columns represent time series ordered samples, color-coded according 
to cell type and time point. Rows represent hierarchically clustered analytes. Analyte levels are mean-
centered and unit-variance on a per-metabolite basis. Three intracellular analyte clusters show clear 
temporal dependence. In group 1, OCC analyte levels are consistently high while OCSC analyte levels 
increase after 30 minutes. Group 2 analyte levels are consistently higher in OCCs while OCSCs start high 





Figure 2.4: Time series plots of metabolite groups determined from clustered heatmap analysis. 
Plots of metabolite levels over time with groups determined from clusters assigned from heatmap 
analysis. Thin lines represent individual metabolite median levels and thick lines represent complied 
median level for the metabolite group. Normalized peak area has been log transformed and autoscaled.A) 
Metabolites from cluster 1 from time series ordered hierarchical clustering with OCC metabolite levels 
higher than OCSC metabolite levels. B) Metabolites from cluster 3 from time series ordered hierarchical 
clustering with OCSC metabolite levels higher than OCC metabolite levels. 
2.2.3. Gene set and metabolic pathway enrichment analysis results show 
strong concordance 
Using metabolite pathway enrichment analysis (MPEA) in MetaboAnalyst, 36 pathways were 
found to be significantly enriched for intracellular metabolic differences between OCCs and 
OCSCs, listed in Table 2.2. Gene set enrichment analysis (GSEA) revealed 11 KEGG pathways 
significantly enriched in OCSC phenotype, listed in Table 2.3. Out of those 11 pathways, only 
six include metabolic reactions that convert endogenous metabolites, four of which overlapped 
with the pathway results from MPEA: (i) arginine and proline metabolism, (ii) fructose and 
mannose metabolism, (iii) primary bile acid biosynthesis, and (iv) steroid hormone biosynthesis. 
This close overlap in the GSEA and MPEA results suggests strong concordance between 
transcriptional and metabolomic data and supports the validity of the identified differences. 
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Table 2.2: Significantly enriched KEGG pathways determined using metabolite pathway 
enrichment analysis. 
KEGG Pathway p value FDR 
Butanoate metabolism 3.19E-11 1.37E-09 
beta-Alanine metabolism 1.84E-10 3.95E-09 
Arginine and proline metabolism 1.32E-09 1.89E-08 
Alanine, aspartate and glutamate metabolism 1.97E-09 2.12E-08 
Tyrosine metabolism 1.05E-08 9.07E-08 
Phenylalanine metabolism 4.50E-08 3.22E-07 
Citrate cycle (TCA cycle) 5.36E-08 3.29E-07 
Aminoacyl-tRNA biosynthesis 4.60E-07 2.47E-06 
Nicotinate and nicotinamide metabolism 7.96E-07 3.80E-06 
Glutathione metabolism 2.96E-06 1.27E-05 
Lysine degradation 4.76E-06 1.71E-05 
Lysine biosynthesis 4.39E-06 1.71E-05 
Fructose and mannose metabolism 8.70E-06 2.88E-05 
Nitrogen metabolism 3.32E-05 1.02E-04 
Histidine metabolism 3.87E-05 1.11E-04 
Glycerolipid metabolism 4.80E-05 1.29E-04 
Primary bile acid biosynthesis 5.48E-05 1.39E-04 
Valine, leucine and isoleucine biosynthesis 6.83E-05 1.47E-04 
Porphyrin and chlorophyll metabolism 6.68E-05 1.47E-04 
Valine, leucine and isoleucine degradation 6.83E-05 1.47E-04 
D-Glutamine and D-glutamate metabolism 7.62E-05 1.56E-04 
Glyoxylate and dicarboxylate metabolism 1.12E-04 2.18E-04 
Biotin metabolism 1.67E-04 3.12E-04 
Pantothenate and CoA biosynthesis 2.06E-04 3.69E-04 
Glycerophospholipid metabolism 2.77E-04 4.76E-04 
Steroid hormone biosynthesis 3.94E-04 6.52E-04 
Glycine, serine and threonine metabolism 8.93E-04 1.32E-03 
Pyrimidine metabolism 8.90E-04 1.32E-03 
Cyanoamino acid metabolism 8.93E-04 1.32E-03 
Purine metabolism 1.89E-03 2.63E-03 
Thiamine metabolism 1.89E-03 2.63E-03 
Pyruvate metabolism 2.93E-03 3.86E-03 
Galactose metabolism 2.96E-03 3.86E-03 
Cysteine and methionine metabolism 4.05E-03 5.12E-03 
Methane metabolism 7.23E-03 8.89E-03 




Table 2.3: Gene set enrichment analysis: KEGG pathways significantly enriched in OCSC 
phenotype 
KEGG Pathway p value FDR q-val 
Fructose and mannose metabolism 0.00000 0.01334 
Metabolism of xenobiotics by cytochrome P450 0.00000 0.07636 
Renin-angiotensin system 0.00960 0.09388 
Glycosaminoglycan biosynthesis-keratan sulfate 0.00606 0.10337 
Starch and sucrose metabolism 0.01152 0.10737 
ABC transporters 0.00191 0.11004 
Drug metabolism-other enzymes 0.00971 0.11724 
Primary bile acid biosynthesis 0.01200 0.12187 
Arginine and proline metabolism 0.01304 0.12491 
PPAR signaling pathway 0.00378 0.13570 
Steroid hormone biosynthesis 0.01232 0.15972 
 
One of these pathways, arginine and proline metabolism, was particularly interesting based on 
the number of metabolites found within the pathway that were each individually statistically 
significantly different in OCSCs as compared to OCCs. These six metabolites (aspartate, 
fumarate, glutamate, gamma-aminobutyric acid, proline, and putrescine) were all found to be 
lower in OCSCs than OCCs, as seen in Figure 2.5. Two of these metabolites, proline and 
putrescine, demonstrated strong concordance between their levels and the levels of 
corresponding enzymes immediately upstream and downstream in the metabolic pathway, as 
shown in Figure 2.6, justifying a closer look at the role that these two metabolites can play in 
cancer and cancer stem cells. In order to further confirm the identity of proline and putrescine, 
pure standards were run on the GC-MS and compared to the intracellular samples. The retention 
times and mass spectra of the two standards were consistent with those of the annotated 




Figure 2.5: Metabolites in arginine and proline metabolism differ significantly between OCCs and 
OCSCs. All of the identified metabolites within the arginine and proline pathway were statistically 
significantly different between OCCs and OCSCs (FDR < 0.05) and were depleted in OCSCs. Box and 
whisker graphs depict the normalized peak area differences between the two cell types: dark black lines 
are the median, boxes identify the middle 50% values, dashed lines show two standard deviation bounds, 





Figure 2.6: Metabolic and transcriptional differences between OCCs and OCSCs in arginine and 
proline metabolism. Differences are shown on the modified KEGG arginine and proline metabolism 
pathway (pathway is modified to show only reactions involved in human metabolism). Boxes with red 
and blue outlines are genes up-regulated and down-regulated, respectively, in OCSCs as compared to 
OCCs. Metabolites with blue ovals have lower levels in OCSCs compared to OCCs. 
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2.2.4. Proline & putrescine have been implicated in cancer 
Putrescine is a polyamine, a class of molecules that has been shown to play an important role in 
cell growth and survival.15, 16 Polyamines have been shown to affect numerous processes in 
normal and cancer cells, including proliferation, apoptosis, cell-cell interactions, and 
angiogenesis.17 Specific mechanisms underlying these modes of action have not yet been 
completely elucidated; however, their critical role in DNA replication is supported by the 
reduced rate of DNA elongation and S-phase arrest in polyamine depleted cells.18 Total 
polyamine levels are higher in highly proliferative cells, like cancer cells, and lower in cells with 
low proliferation rates.16 However, we note that the medium control experiment, which induced 
significantly slower growth in OCCs, did not induce a change in putrescine levels, suggesting 
that a decrease in proliferation is not necessarily the cause of decreased putrescine levels. 
Polyamine catabolism has been implicated in cancer, as the process can cause DNA damage and 
mutation via production of reactive aldehydes, production of reactive oxygen species (ROS), or 
depletion of free radical scavengers.19 Many cancer therapeutics have been targeted toward 
enzymes in the polyamine metabolism pathway, with promising initial results.19, 20  
Likewise, proline metabolism is important to cellular processes, both in its catabolism and 
anabolism, and has been implicated in cancer.21-23 Proline catabolism by proline 
dehydrogenase/oxidase (PRODH/POX) produces pyrroline-5-carboxylate, along with free 
electrons that can either be donated to the electron transport chain or used to generate ROS. 
During periods of high stress, PRODH/POX expression is induced to help rescue the cell through 
energy production or produce ROS to induce autophagy. Proline anabolism from glutamate has 
been implicated in cancer via its control by the transcription factor MYC, which represses 
PRODH/POX expression though microRNA control and induces expression of P5CS and PYCR, 
enzymes that convert glutamate to proline.24 During glutamate conversion to proline, NAD(P)+ is 
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regenerated from NAD(P)H for possible use in glycolysis and the pentose phosphate pathway. 
Knockdown of P5CS or PYCR has been shown to inhibit anaerobic glycolysis, thus indicating 
that proline anabolism from glutamate contributes to establishment of the Warburg effect.24 
2.2.5. Differences in proline & putrescine levels between OCCs and OCSCs 
may be explained by stem cell metabolism 
With both proline and putrescine and their respective pathways known to be already altered in 
cancer compared to normal tissues, it is perhaps surprising to find that both of these metabolites 
are now altered again in OCSCs relative to OCCs. The metabolic similarities between cancer 
stem cells and normal stem cells have already been widely commented upon – for example, both 
reprogram their energy metabolism to aerobic glycolysis to help support immortality.25, 26 
Reprogramming to aerobic glycolysis is characteristic of cancer cells in general, though, and 
therefore can not be used as a distinguishing characteristic of stem cell metabolism. Though stem 
cell metabolism is a field with significantly fewer published reports than cancer metabolism, 
recent discoveries in the field can begin to shed light on the biological meaning behind the 
changes of proline and putrescine in OCSCs given their previously-known alterations in cancer. 
Putrescine has long been known to promote differentiation. More recently, in a study comparing 
mouse embryonic stem cells (mESCs), induced pluripotent stem cells (iPSCs), and fibroblasts, 
polyamine levels were found to be statistically significantly reduced in iPSCs, though 
interestingly they were similar between fibroblasts and mESCs.27 In a systems-scale comparison 
of metabolite levels between mESCs and iPSCs, polyamines were one of the few metabolite 
groups that showed a difference between the two cell types; the others were amino acids and 
phosphatidylcholine and phosphatidylethanolamine lipid structures (not measured in this work). 
This finding suggests that OCSCs may generally occupy a state similar to iPSCs, with a shift 
from standard cancer metabolism towards a more stem-like metabolism, but not necessarily 
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identical to the normal stem cells that they in some ways emulate. In this case, the depletion of 
putrescine, with its role in differentiation, may help to maintain the OCSCs in a more stem-like 
state. 
Proline has recently been shown to induce differentiation in mESCs towards an epiblast stem cell 
state.28, 29 By adding biologically relevant concentrations of proline to mESC media, changes 
were noticed in proliferation, phenotype, and differentiation kinetics. These changes were similar 
to the ones caused by addition of MEDII media to the normal stem cell media, a common 
protocol for initiating differentiation of mESCs.28 Further investigation showed that these 
changes were induced by catabolism of proline to pyrroline-5-carboxylate.29 In addition, proline 
has been shown to act as a signaling molecule that controls stem cell behavior via an epigenetic 
mechanism.17 This suggests that OCSCs may use proline metabolism in a similar way to stem 
cells and by keeping a lower intracellular concentration of proline, the OCSCs help retain their 
stemness. 
Taken together, then, the trends identified are consistent in the context of what is known at the 
intersection of both the cancer metabolism and stem cell metabolism fields. While it is to be 
expected that proline and putrescine are accumulated in OCCs based on their roles in or 
correlations with proliferative phenotypes and cancer metabolism, these metabolites would 
display effects suppressing the observed stem cell-like phenotypes of OCSCs. Specifically, high 
levels of either of these metabolites may tend to promote differentiation of OCSCs into less 
stem-like cell types, and thus maintenance at lower levels would facilitate the stemness 
associated with cancer stem cells. 
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2.2.6. Comparison of OCSC differences to other cancer stem cell studies 
An interesting picture emerges when differences in metabolite abundances between OCCs and 
OCSCs are compared with differences in metabolite abundances between ovarian borderline 
tumors and invasive ovarian carcinomas. While tissue concentrations of glycine, proline, 
glutamate, and fumarate are higher in invasive ovarian carcinomas relative to non-invasive 
borderline tumors,30 our data show that OCSCs display lower concentrations of these metabolites 
relative to OCCs. Glycine plays a role in rapid proliferation of cancer cells via the glycine 
biosynthesis pathway10 and the SOG pathway31. The SOG pathway consists of serine synthesis, 
one-carbon metabolism, and the glycine cleavage system and supports rapid proliferation 
through energy production. Considering the role of glycine in rapid proliferation of cancer cells, 
the role of fumarate in the malignant phenotype via aberrant activation of hypoxia response 
pathways,32 and the role of glutamate in anabolic processes and replenishing of the tricarboxylic 
acid cycle intermediates during cell growth (anaplerosis),33 it is somewhat intriguing that OCSCs 
are metabolically more similar to indolent and relatively benign borderline tumor cells with 
respect to these cancer-relevant metabolites. We hypothesize that certain phenotypic similarities 
between cancer stem cells and cells with less malignant potential (or non-malignant cells), might 
be associated with quiescence of these cell types and might play an important role in failure of 
cancer therapies designed to target aggressively growing clinical cancers. Similarly, our results 
imply that OCSCs are less dependent on polyamines than their more differentiated progeny, 
which may not be purely growth-associated (as discussed in greater detail above). This lower 
dependence of OCSCs on polyamines could be a more broadly applicable property of quiescent 
cancer stem cells that can explain the general failure of inhibitors of polyamine synthesis in 
clinical cancer trials.17  
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Our results are also partially consistent with a recent metabolomics study of glioma-stem cells 
(GSCs), specifically the cultured GSCs (CGSCs). The in vivo tumors formed from CGSCs were 
noted to have increased concentrations of glycine and choline-containing compounds and 
decreased concentrations of glutamine, glutamate, taurine, and total creatine.13 In our results, we 
did not detect choline-containing compounds, taurine, or creatine. We did, however, notice 
decreasing trends in both glycine and glutamate. One caveat on comparing these two 
experiments, though, is that the CGSCs were compared to normal tissue, while our OCSCs were 
compared to cancerous cells.  
2.2.7. Limitations 
In this work we did not use control cells that would represent cells of origin or nonmalignant 
counterparts of epithelial ovarian cancer cells, since our primary interest was the identification of 
metabolic differences that can explain other biological differences between OCSCs and their 
more differentiated progeny (e.g. quiescence and drug resistance) rather than cancer vs. normal 
metabolomic differences that have already been more widely examined. Furthermore, 
identification of the appropriate normal control would be complicated, if not impossible, due to 
the fact that the cell of origin of epithelial ovarian cancers is still debated. Thus, the strength of 
our work is in that we compare the metabolism of isogenic cancer cell lines that differ only in 
their cell stemness and differentiation status. 
We also note that the extent of biological interpretation of our data has been limited by the 
content of available databases and by conservative data processing decisions meant to increase 
confidence in the results. The metabolites used in our data analyses are not only limited by our 
ability to establish the biochemical identities of metabolites measured by our instrument using 
mass spectral databases, but also by the incompleteness of databases available for pathway-level 
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analysis. We have also used a high similarity threshold during chromatogram processing to 
ensure that, when a metabolite is assigned a name, we have high confidence that the assigned 
name accurately reflects the metabolite’s identity. Based on these conservative decisions, we 
have thus potentially omitted other significant metabolites that did not meet confidence 
thresholds or were not available in the databases we used. Thus, there may be further support for 
any of the pathways discussed here, or potentially even for other pathways, as being important to 
OCSC metabolism; only with further refinement of pathway databases and analytical tools can a 
more thorough biological analysis be performed. 
Finally, this work only studied one specific cancer cell line and its isogenic cancer stem cell line. 
It would be desirable to perform similar analyses for multiple isogenic cancer stem cell/cancer 
cell line pairs, as cancer is well-known to be a heterogeneous disease. However, there are very 
few ovarian cancer stem cell lines in existence, and none available in repositories for purchase. 
As such, the next steps in this work would be to derive or acquire more of such cancer stem cell 
lines to verify the broad applicability of the results obtained here. 
2.3. Conclusions 
Overall, we have shown that an OCC line and its derived OCSCs have different metabolic 
profiles that are consistent with predictions based on previously observed transcriptional profiles. 
Both multivariate and univariate data analyses indicate that there are many significant 
differences in the metabolism of these two isogenic cell types; however, none of these 
differences were previously known. Analysis of the metabolic and transcriptional differences 
between these OCCs and OCSCs revealed the arginine and proline metabolism pathway as 
playing a particularly important role in the differences between the cell types. Proline and 
putrescine both play important roles in cancer, and have been identified as serving important 
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roles in stem cell metabolism. The conflicting roles for these metabolites in these two different 
contexts may place them in a delicate balance in OCSCs. Proline and putrescine thus may play a 
major role in the maintenance of the OCSC phenotype.  
2.4. Methods 
2.4.1. Cell culture 
The OVCAR-3 cell line was obtained from the Developmental Therapeutic Program (DTP) of 
the National Cancer Institute (NCI). The OVCAR-3 ovarian cancer cells (OCCs) were cultured 
in R10 medium: RPMI-1640 (Cellgro, Mediatech Inc., Manassas, VA) supplemented with 10% 
fetal bovine serum (FBS, Invitrogen, Grand Island, NY) and 1% antibiotic-antimycotic solution 
(Cellgro, Mediatech Inc., Manassas, VA). Authenticity of the OVCAR-3 cell line was confirmed 
using short tandem repeat profiling performed by IDEXX RADIL (Columbia, MO) in October 
2013. Cells were grown until confluence and subcultured at a ratio of 1:4. Immediately before 
any time-course sampling began, OCCs were passaged and seeded in 6-well plates (Greiner Bio-
One, Monroe, NC) with a surface area of 6.9 cm2 at a density of 3x105 cells/well (4.35x104 
cells/cm2) and incubated for 24 hours in 2 mL R10 medium to allow the cells to attach and 
recover; the medium was removed, wells were washed once with PBS, and then 2 mL of fresh 
R10 medium was added to begin the experiment. 
Ovarian cancer stem cells (OCSCs) were previously derived from a side population of OVCAR-
3. OCSCs are less adherent than OVCAR-3 cells and, unlike OVCAR-3 cells that are grown as 
adherent monolayers, are grown as spheroids in stem cell media to help support their stemness as 
previously described.8 Briefly, the OCSCs were cultured in ultra-low attachment petri dishes 
(Corning Incorporated, Corning, NY) in stem cell medium: DMEM/F12 (1:1) (Cellgro, 
Mediatech Inc., Manassas, VA) supplemented with 0.4% bovine serum albumin (BSA, Sigma-
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Aldrich, St. Louis, MO), 20 ng/mL epidermal growth factor (EGF, Invitrogen, Grand Island, 
NY), 10 ng/mL basic fibroblast growth factor (bFGF, Sigma-Aldrich, St. Louis, MO), 5 µg/mL 
insulin (Sigma-Aldrich, St. Louis, MO), and 1% antibiotic-antimycotic solution (Cellgro, 
Mediatech Inc., Manassas, VA). The spheroids were dissociated and reseeded at a density of 105 
cells/mL each week. To begin the time-course experiment, OCSCs were dissociated and seeded 
into ultra-low attachment 6-well plates (Corning Incorporated, Corning, NY) with a surface area 
of 6.9 cm2 containing 2mL of fresh stem cell medium at a density of 3x105 cells/well. Both the 
OCC and OCSC experiments were performed in biological triplicate. 
2.4.2. Sampling Protocols 
Samples were taken at 0 minutes, 15 minutes, 30 minutes, 8 hours, 24 hours, and 48 hours to 
capture both short- and long-term metabolic profiles. For OCCs, medium was removed and snap 
frozen in liquid nitrogen for extracellular analysis. Cells were then quickly washed with 1mL 
PBS at 37°C, which was aspirated off, and then 700 µL of 80:20 methanol/water solution at -
80°C was added immediately. The plate was then incubated at -80°C for 15 minutes. After 
incubation, remaining cellular debris were harvested using a cell scraper (BD Falcon, San Jose, 
CA) for intracellular analysis. For OCSC cells, the media-cell mixture was transferred to a 15 
mL centrifuge tube and centrifuged at 1,900 g for 30 seconds at room temperature. The 
supernatant was removed and snap frozen in liquid nitrogen for extracellular analysis. The cell 
pellet was quickly resuspended in 1mL PBS at 37°C and then immediately centrifuged again at 
1,900 g for 30 seconds at room temperature. The wash solution was discarded and the cell pellet 
was resuspended in 700 µL of 80:20 methanol/water at -80°C. The samples were then incubated 
at -80°C for 15 minutes. 
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For both cell types, the intracellular solution was then transferred to a microcentrifuge tube in a 
cold ethanol bath and centrifuged at 5,000 g for 5 minutes at -4°C. The supernatant was retained, 
and the pellet was subsequently re-extracted twice in 100 µL of the cold 80:20 methanol/water 
solution, with all supernatants being pooled.34 Intracellular and extracellular samples were stored 
at -80°C and -20°C, respectively, until analysis. 
2.4.3. Media Control 
To control for the differences in media, a secondary experiment was performed where OCCs 
were grown in parallel in their normal media and OCSC media (both media formulations are 
described above) for 48 hours. Intracellular and extracellular samples were taken at 0, 24, and 48 
hours in the same manner as described above for the OCCs. Cell counts were also taken (data not 
shown) and it was discovered that OCCs grow slower in the OCSC medium than they do in their 
normal medium, mimicking the slower growth rate of OCSCs. Intracellular and extracellular 
samples were analyzed and on the GCxGC-MS and processed with the OCC and OCSC data (as 
described in section 2.4.7).  
2.4.4. Extracellular Sample Extraction 
Immediately before two dimensional gas chromatography-mass spectrometry (GCxGC-MS) 
analysis, an acetonitrile precipitation was performed on the extracellular samples to remove 
protein.35 Briefly, the extracellular samples were thawed on ice and 75 µL was removed for 
GCxGC-MS analysis. 150 µL of ice-cold acetonitrile was added to the sample, and the sample 
was vortexed for one minute. The sample was then centrifuged at 21,100 g for 7 minutes, and the 
supernatant removed for GCxGC-MS analysis. 
2.4.5. GCxGC-MS Analysis 
Before derivatization, both intracellular and extracellular samples were vacuum concentrated in a 
CentriVap at 40°C until completely dry. For the intracellular samples, a volume equated to 
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7.5x104 cells for each sample was vacuum concentrated in order to achieve a concentration of 
3x104 cells equivalents/µL after derivatization. For the extracellular samples, the entire 
supernatant from the extracellular extraction was vacuum concentrated.  
The samples were derivatized following the protocol laid out by Fiehn, et. al.36 Briefly, 10 µL 
(extracellular) or 2.5 µL (intracellular) of 40 mg/mL O-methylhydroxylamine hydrochloride (MP 
Biomedicals, LLC, Santa Ana, CA) in pyridine was added to the dried sample and shaken at 
1400 rpm for 90 minutes at 30°C. 90 µL (extracellular) or 22.5 µL (intracellular) of N-methyl-N-
(trimethylsilyl) trifluoroacetamide (MSTFA) + 1% trimethylchlorosilane (TMCS) (Thermo 
Scientific, Lafayette, CO) was then added to the samples which were then shaken at 1400 rpm 
for 30 minutes at 37°C. Samples were centrifuged at 21,100 g for 3 minutes and 50 µL 
(extracellular) or 15 µL (intracellular) of the supernatant was added to an autosampler vial. 
Samples were spiked with 0.25 µL (extracellular) or 0.10 µL (intracellular) of a retention time 
standard solution consisting of fatty acid methyl esters (FAMEs) and an internal standard of 
nonadecanoic acid methyl ester dissolved in dimethylformamide. 
A LECO Pegasus 4D instrument with an Agilent 7683B autosampler, Agilent 7890A gas 
chromatograph and time-of-flight mass spectrometer (TOF-MS) was used to analyze the 
samples. The first column was an HP-5, 30 m long x 0.320 mm ID x 0.25 µm film thickness 
(Agilent, Santa Clara, CA), and the second was an Rtx-200, 2 m long x 0.25 mm ID x 0.25 µm 
film thickness (Restek, Bellefonte, PA). Specific autosampler, gas chromatography, and mass 
spectrometry methods can be found in Appendix A. 
2.4.6. Data Analysis 
Sample runs were first analyzed in ChromaTOF (LECO, St. Joseph, MI) to determine baseline, 
peak area, and peak identification. Briefly, settings included a baseline offset of 0.5, automatic 
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smoothing, 1st dimension peak width of 10 seconds, 2nd dimension peak width of 0.10 seconds, 
and a match of 700 required to combine peaks with a minimum signal-to-noise (S/N) of 5 for all 
subpeaks. Peaks were required to have a S/N of 10 and have a minimum similarity score of 800 
before assigning a name. Unique mass was used for area and height calculation.  
To align the samples, MetPP (http://metaopen.sourceforge.net/metpp.html) was used.37 Sample 
files and a derivatization reagent blank file were uploaded from ChromaTOF. Unknowns were 
retained during the peak alignment process. The derivatization reagent blank file was used to 
subtract peaks attributable only to derivatization reagents from the sample files. On-the-fly 
alignment was used with quality control samples manually selected as the peak list for primary 
alignment. Peak alignment was performed using the default criteria. 
After alignment, further processing of the data was done following the procedure laid out by 
Dunn, et. al.38 Batch effects were removed from the intracellular data set using LOESS. During 
LOESS correction, one of the OCC and OCSC 24 hour biological replicates were identified as an 
outlier and removed. LOESS was also performed on the extracellular data set, but batch effects 
were amplified in the samples after correction due to quality control (QC) sample run errors so 
the original data set was used for subsequent analysis. To remove analytes that were not 
reproducibly detected, analytes for which more than half of the values were missing in the QC 
samples or for which the QC samples had a coefficient of variance larger than 0.5 (excluding 
missing values) were removed from the data set. Then, missing values were manually corrected 
using small value correction only if all the values were missing in a set of biological replicates. 
Finally, MetaboAnalyst (http://metaboanalyst.ca/) was used for statistical and enrichment 
analysis, applying both the statistical analysis and time series analysis modules.39 For both 
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analyses, remaining missing values were k-nearest neighbors (KNN) imputed. Data was filtered 
using the interquantile range method and then log-transformed using generalized logarithm 
transformation (base 2) and autoscaled.  
For removal of media effects, the media control samples were isolated from the OCC and OCSC 
samples and analyzed using MetaboAnalyst. Any metabolites found to have significant 
differences (t-test, all time points, FDR < 0.05) in the media control experiment were then 
removed from the main data set to eliminate any metabolic changes due to media differences. 
This was done for both the intracellular and extracellular data sets. 
For enrichment analysis, both metabolite set enrichment analysis (MSEA) and metabolite 
pathway enrichment analysis (MPEA) yielded similar results, so only MPEA results were 
considered further. The entire time series was uploaded as discrete data with compound names. 
Metabolites were properly matched to their HMDB codes before processing the data. Data 
processing followed the same steps as listed above for missing value imputation and data 
normalization. The Homo sapiens pathway library was used for analysis and an in-house 
metabolite reference library based on detectable metabolites for our system was uploaded. 
Global test was used for pathway enrichment analysis, with relative-betweeness centrality as the 
pathway topology analysis. Pathways with an FDR < 0.05 were considered significantly 
enriched.  
For gene set enrichment analysis (GSEA) of OCSC and OCC gene expression data, .CEL files 
corresponding to 3 replicated cultures of OCSC and OCC (GeneChip® Human Genome U133 
Plus 2.0 Array), generated as previously described8, were processed and normalized by GCRMA 
method (http://arrayanalysis.org) and used for GSEA 
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(http://www.broadinstitute.org/gsea/index.jsp) without pre-filtering of probe sets using the 
following parameters: OCC vs. OCSC as categorical phenotypes; signal-to-noise metric; gene set 
permutation type; curated KEGG gene sets (186 gene sets, Molecular Signatures Database v4.0). 
Gene sets were considered significantly enriched in a given phenotype if their FDR q value was 
< 0.20. The dataset employed in this analysis is available in the Gene Expression Omnibus 
(GEO, http://www.ncbi.nlm.nih.gov/geo/) as series GSE28799.  
2.4.7. Effects due to growth media differences successfully removed from 
OCC vs OCSC intracellular metabolomics data 
OCSCs require stem cell medium to retain their stem-like properties and therefore, they are 
grown in different media than the OCCs. Since growth in different media could cause metabolic 
changes and confound the metabolic differences seen between the two cell types, we designed a 
media control experiment that would allow us to remove any metabolic changes due purely to 
media effects. OCCs were grown in their normal R10 medium and in stem cell medium and 
intracellular and extracellular samples were taken at 0, 24, and 48 hours. These samples were 
analyzed and processed with the OCC and OCSC intracellular and extracellular samples. The 
media control samples were then isolated from the OCC and OCSC samples and analyzed on 
their own. Any analyte identified as statistically different between only the media control 
samples was removed from the entire data set.  
Before removing the analytes with statistically significant differences from the intracellular 
dataset, the samples from the two different media types separated in principal component (PC) 2, 
seen in Figure 2.7A. Even though separation is seen between these two media controls, it is 
captured in PC2, which represents a smaller proportion of the overall variance than the 
separation between OCCs and OCSCs, captured in PC1. Once the significant analytes were 
removed, the separation decreased between the two media controls in the all analyte dataset 
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(Figure 2.7B) and no principal components analysis (PCA)-based separation could be found 
based on annotated metabolites only (Figure 2.7C), showing that the differences between OCC 
and OCSC intracellular metabolism are not simply due to growth in different media. The 
intracellular datasets with media effects removed are the basis for all of the biologically-related 
discussion following, and so any differences in these analytes between OCCs and OCSCs should 
not be attributed to medium differences.  
In the extracellular dataset, a large difference between the OCCs in R10 medium and OCCs in 
stem cell medium was seen before removal of the statistically different analytes, as seen in 
Figure 2.8A. After removal, in both the unknown and known compound data set and the 
metabolite only data set, there is still separation visible between the two media control samples 
(Figure 2.8B and C). This separation is less than that seen between the OCC and OCSC 
extracellular samples, but because the media effect was not completely removed, we will focus 




Figure 2.7: Intracellular media effects are successfully removed from OCC vs OCSC comparisons. 
Principal components analysis of OCC (red), OCSC (blue), and the two media control (OCCs grown in 
R10 medium (green) and stem cell medium (cyan)) intracellular samples. OCCs (red) and OCCs grown in 
R10 medium (green) are similar samples, but the OCCs grown in R10 medium were grown at a different 
time than OCCs and only have three time points instead of six. (A) Media effects are clearly seen in PC 2 
through the separation of two media control samples. (B) After removing media effects, the two media 
control samples are overlapping, showing the reduction of media effects in the intracellular analysis. (C) 




Figure 2.8: Extracellular media effects cannot be removed through simple removal of statistically 
significantly different analytes. Principal components analysis of OCC (red), OCSC (blue), and the two 
media control (OCCs grown in OCC media (green) and OCSC media (cyan)) extracellular samples. (A) 
OCCs (red) and OCCs grown in R10 medium (green) are similar samples, but the OCCs grown in R10 
medium were grown at a different time than OCCs and only have three time points instead of six. Media 
effects are clearly seen in PC 1 through the separation of two media control samples. (B) After removing 
media effects, the two media control samples are closer, showing the reduction of media effects, but are 
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Chapter 3 Chemotherapeutic and environmental perturbations 
cause different metabolic responses in an ovarian cancer stem cell 
line compared to its isogenic parental cell line 
3.1. Introduction 
Since 1924, when Warburg discovered anaerobic glycolysis, it has been known that cancer 
cellular metabolism is distinct from normal cellular metabolism.1, 2 It is only recently that the 
important role metabolism plays in cancer has become more generally recognized. Dysfunctional 
metabolism is now acknowledged as a hallmark of cancer, and multiple different examples of 
altered metabolism in cancer cells have been demonstrated.3, 4 Most cancer cellular metabolism 
studies are usually performed using in vitro cell culture. Cell culture conditions are ideal: an 
overabundance of an energy source (usually in the form of glucose) is supplied, oxygen 
concentration is kept high, and cells are grown in monolayers to keep nutrient and oxygen 
transfer high to all cells. Unfortunately, these in vitro conditions drastically differ from the 
conditions found in vivo in the tumor environment, which are far from ideal. With the fast 
growth of tumors, angiogenesis cannot occur quickly enough to supply the entire tumor with 
capillaries, resulting in nutrient fluctuations, hypoxia, and ischemia (a state of depleted oxygen 
and glucose) – particularly in the center of tumor. Along with poor cellular growth conditions, 
most tumors are also treated with chemotherapeutics to attempt to eradicate the tumor. These 
differences in environmental conditions can actually be critical in correctly understanding and 
treating cancer cells. For example, differences between in vitro cellular growth conditions and 
the in vivo tumor environment have been identified as responsible for the inconsistency in 
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clinical and in vitro lethal concentration for metformin.5 It is thus critical to attempt to study 
cancer cells under conditions relevant to their natural tumor environment.  
Another important characteristic of tumors that may not be well represented in in vitro models is 
the heterogeneous population of cancer cells. Part of the heterogeneous population are cells 
referred to as cancer stem cells due to their stem-like properties: they can differentiate and self-
renew, and they are chemo and radio-resistant. Thus, to fully understand tumor metabolism we 
must characterize the metabolism of both cancer cells and cancer stem cells. Any differences in 
metabolic behaviors between these two cells types could allow us to start to understand how the 
two different cell types handle some of the stresses encountered in a tumor. Understanding the 
metabolic effects of these stresses could lead to a more complete model of cancer pathology and 
the development of metabolism-targeted cancer therapies. 
Here, we use ovarian cancer cells (OCCs) and ovarian cancer stem cells (OCSCs) as a model 
system for isogenic cancer cells and cancer stem cells. We subjected them to biologically 
inspired environmental in vitro perturbations and measured their metabolic responses. Since 
OCCs and OCSCs are already known to exhibit significant metabolic differences during normal 
growth,6 we hypothesized that these two cell types may also have differing metabolic responses 
to the environmental perturbations. The perturbations used in this study are glucose deprivation, 
hypoxia, ischemia, and chemotherapeutic treatment. Docetaxel, a common first line treatment for 
ovarian cancer, was chosen as the chemotherapeutic. These perturbations are applied over a 
period of 48 hours with metabolomics measurements being made throughout that period using 
two-dimensional gas chromatography-mass spectrometry (GCxGC-MS).  
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3.2. Results & Discussion 
3.2.1. Univariate analysis and time series analysis reveals no metabolic 
change for OCSCs upon docetaxel treatment 
To profile cellular metabolism, GCxGC-MS was used to analyze the intracellular samples 
collected during the docetaxel treatment for both the OCCs and OCSCs. Both unknown analytes 
and annotated analytes result from this data processing pipeline. Because of the limited scope of 
metabolite mass spectrum databases and the conservative identification cutoff we employ in data 
processing, some of the unannotated analytes may be endogenous metabolites that have not yet 
had a mass spectrum deposited in a database, or their mass spectral similarities to library spectra 
may fall under our conservative naming cutoff. Therefore, these unknown analytes can still be 
important to the metabolic profile of the cells, and so they were included for most downstream 
analyses except enrichment analyses (which require metabolite identifies). Lists of annotated 
metabolites in this work come from unique matches to known human metabolites in either the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) or the Human Metabolome Database 
(HMDB), followed by a manual confirmation of similarity between the annotated peak spectrum 
and the library spectrum. For the OCCs, 198 reproducible analytes were detected, including 
unknown analytes and annotated analytes that were not included in human metabolic databases, 
with 46 unique metabolites were annotated as known human metabolites. For the OCSCs, 115 
reproducible analytes were detected overall and 31 unique metabolites were mapped to either 
KEGG or HMDB.  
For OCSCs, univariate analysis in MetaboAnalyst revealed no statistically significant differences 
(FDR corrected p value < 0.05) between the control and docetaxel treated cells overall (t test 
across all time points). When looking at the individual time points, only one unknown analyte 
was found to be statistically significantly different between the control and docetaxel treated 
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cells, at 48 hours. For the OCCs, on the other hand, significant metabolome-scale changes were 
apparent during univariate analysis. Analysis of variance (ANOVA) was used to determine the 
differences between the three treatments: docetaxel at IC50, docetaxel at 1.5x IC50, and control. 
The number of statistically significant analytes found during ANOVA is shown in Table 3.1. 
Two-sample t tests were also performed on each individual docetaxel treatment versus control, 
with the number of statistically significant analytes shown in Table 3.1.  
Table 3.1: Number of statistically significant analytes found in OCC analysis. The number of 
statistically significant analytes (FDR < 0.05) found during ANOVA (Control vs IC50 vs 1.5x IC50) or t-
test analysis (Control vs IC50 and 1.5x IC50). 
Time Points Control vs IC50 vs 1.5x IC50 Control vs IC50 Control vs 1.5x IC50 
All 31 18 24 
24 22 15 14 
48 22 8 8 
 
Two-way ANOVA was used to identify FDR-corrected p values for group, time, and interaction 
effects. Group effects relate to the difference in analytes between the experiment conditions, the 
time effect measures how the analyte changes with time across all the conditions, and the 
interaction effect captures effects where the combination of time and group effects are not 
additive. Analysis of the OCSC intracellular data using two-way ANOVA again demonstrated 
very little change over time between the control and docetaxel treated cells, with only two 
analytes showing statistically significant differences in the group category; neither of these were 
analytes that mapped to an annotated metabolite. Two-way ANOVA on OCC intracellular data 
revealed many more analytes that were statistically significantly different between the two 
docetaxel treatments and control cells than were found using one-way ANOVA. The numbers of 
metabolites with statistically significant effects are shown in Table 3.2.  
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Table 3.2: Number of statistically significantly different analytes in OCC using two-way ANVOA 
time series analysis. The number of statistically significant analytes (FDR < 0.05) found during time 
series analysis using two-way ANOVA. 
Category Control vs IC50 vs 1.5x IC50 Control vs IC50 Control vs 1.5x IC50 
Group 42 31 41 
Time 67 48 51 
Interactions 36 29 29 
 
The annotated metabolites identified as having statistically significant group effects are shown in 
Table 3.3 for both docetaxel concentrations and for each concentration individually. All of the 
metabolites identified as statistically significant via one-way ANOVA for both docetaxel 
concentrations were also found as statistically significant via t tests for at least one of the 
concentrations individually. All of the metabolites with significant group effects for either 
concentration also had significant group effects for both docetaxel concentrations together. For 
the 1.5x IC50 concentration, three metabolites, including gamma-aminobutyric acid (GABA), 
were identified as having significant group effects that had not been detectable when analyzing 
both docetaxel concentrations together, suggesting that docetaxel at 1.5x IC50 has greater 
metabolic effects over 48 hours than docetaxel at IC50.   
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Table 3.3: Metabolites identified as statistically significantly different during chemotherapeutic 
treatment using two-way ANOVA for OCCs.
 






















Uracil 2.12E-04 3.65E-12 2.48E-07 
Phosphoric acid 5.77E-04 1.90E-06 3.24E-06 
Arachidonic acid 5.77E-04 1.75E-05 3.24E-06 
Ethanolamine 3.24E-03 1.33E-08 1.11E-04 
D-Glucose 3.38E-03 5.24E-03 6.43E-04 













Uracil 0.019 5.08E-09 1.79E-06 
Phosphoric acid 0.030 1.61E-04 5.39E-04 
Ethanolamine 0.036 4.64E-06 6.99E-04 

















Uracil 3.85E-04 4.65E-07 6.66E-05 
Arachidonic acid 7.39E-03 6.00E-05 9.66E-05 
Hexadecane 0.025 0.287 0.522 
D-Glucose 0.029 0.016 3.59E-03 
Mannose 6-phosphate 0.038 0.320 0.491 
4-Hydroxy-L-proline 0.039 0.262 0.793 
 
Uracil, a nucleobase used for RNA production, allosteric regulation, and as a coenzyme, always 
showed the most significant group effect, most significant time effect, and the most or second 
most significant interaction effect in the three data sets of analyses. Uracil levels in docetaxel 
treated cells spiked at 24 hours (with over 700-fold change from the control) and then leveled off 
at 48 hours, at which time the uracil in the control cells reached similar levels. The quicker 
spiking of uracil levels in docetaxel treated OCCs could be the cell reacting to the stress by 
increasing production of uracil or the docetaxel treatment blocking pathways that utilize uracil. 
These docetaxel-induced changes in uracil levels are particularly noteworthy, as recent clinical 
studies have shown that synthetic analogs of uracil (such as 5-flurouracil or tegafur/uracil), 
which inhibit enzymes using uracil as a substrate, when administered in combination with 
docetaxel cause improved treatment results for gastric cancer, prostate cancer, and lung 
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metastases.7-10 Therefore, if docetaxel treatment does increase cellular dependence on uracil in 
the cells that are somewhat docetaxel resistant, then this would help explain why the addition of 
a competitive inhibitor for uracil improves patient treatment results. 
3.2.2. PCA further confirms metabolic change in OCCs but not in OCSCs 
upon docetaxel treatment 
Principal components analysis (PCA) allows for graphical interpretation of data through 
unsupervised dimensional reduction. PCA on OCSCs alone further supported the results from the 
basic and time series univariate analysis. No separation is evident between control and docetaxel 
treated cells, with the only separation seen between the initial time point and the later time points 
(24 and 48 hours), as shown in Figure 3.1A, and PC1 fully responsible for capturing this 
separation. PCA loading scores indicate that fumarate, psicose, and other unknown analytes are 
responsible for the separation seen in PC1. PCA on only the 24 or 48 hour time points showed 
the same lack of separation between control and docetaxel treated OCSCs. Previous work has 
shown that OCSC viability does not vary greatly over 96 hours of docetaxel treatment.11 Overall, 
this non-perturbation of metabolism suggests quite powerful resistance of the OCSCs to 
docetaxel. Cancer stem cells are generally less susceptible to chemotherapeutic treatments than 
their cancer cell counterparts, but it is not known how susceptible their cellular metabolism is to 
chemotherapeutics. Here, it seems that OCSCs are able prevent any systematic change in 
metabolism, whether through an active role (removing docetaxel or inhibiting docetaxel uptake) 





Figure 3.1: PCA of docetaxel perturbations highlights the different metabolic responses of OCCs 
and OCSCs. PCA of metabolic profiles of OCSCs (A) and OCCs (B) in response to docetaxel over 48 
hours. Dotted ovals represent 95% confidence intervals of the membership of each sample class. (A) PC1 
separates the initial time point and the later times points, but there is no separation between control and 
docetaxel treated cells, suggesting that docetaxel has little to no effect on the metabolism of OCSCs over 
a 48 hour period. (B) PCA shows clear separation between control and docetaxel treated OCCs, as well as 
separation between the two treatment levels, and separation between the time points for all treatments and 
controls. PCI and PC2 both are responsible for the separation between different experimental groups as 
well as time.  
The clear effect of docetaxel on OCC metabolism is further supported with PCA, as seen in 
Figure 3.1B. Docetaxel-treated samples cluster together away from both the control and initial 
samples with distinct separation between the different concentrations and time points. Even 
though the separation is small between the different time points and between the different 
treatment levels (each in different PCs), the differences are clear and consistent. The control 
samples cluster together high in PC1 or PC2, with large variation between the 24 hour samples, 
which lie closer to the initial samples, and the 48 hour samples. The control OCCs have a much 
larger variance between the 24 and 48 hour time points compared to the variance between 
docetaxel treated OCCs. PC1 and 2 seem to be equally responsible for capturing the separation 
between treatment and time points. Unknown analytes, leucine, and fumarate are most important 
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in PC1 separation. For PC2, unknown analytes and glucose are largely responsible for 
separation. 
3.2.3. Metabolite pathway enrichment analysis reveals important pathways in 
metabolic docetaxel response for OCCs 
Metabolic pathway enrichment analysis (MPEA) in MetaboAnalyst found 14 pathways 
statistically significantly enriched for differences between control and docetaxel treated OCCs. 
In order to find only the pathways enriched for docetaxel differences and not between the initial 
state and these treatments, only the 24 and 48 hour time points were included in this analysis. 
Table 3.4 shows the pathways that were enriched. Most of the pathways affected by docetaxel 
are amino acid and carbohydrate metabolism pathways, but pathways involved in nucleotide 
metabolism, cofactor and vitamin metabolism, and lipid metabolism have also been altered. 
Pantothenate and CoA biosynthesis and pyrimidine metabolism both involve uracil, further 
highlighting that docetaxel treatment causes a perturbation in uracil metabolism. 
Table 3.4: Metabolic pathways significantly enriched for differences between control and docetaxel 
treated OCCs. 
KEGG Pathway Raw p FDR 
Amino sugar and nucleotide sugar metabolism 0.002 0.033 
Citrate cycle (TCA cycle) 0.002 0.033 
Glycerophospholipid metabolism 0.004 0.033 
Butanoate metabolism 0.004 0.033 
Nicotinate and nicotinamide metabolism 0.005 0.033 
Alanine, aspartate and glutamate metabolism 0.005 0.033 
Arginine and proline metabolism 0.005 0.033 
Glutathione metabolism 0.007 0.040 
Pyrimidine metabolism 0.010 0.047 
Arachidonic acid metabolism 0.011 0.047 
Pantothenate and CoA biosynthesis 0.013 0.050 
beta-Alanine metabolism 0.014 0.050 




Unsurprisingly, MPEA identified no pathways significantly enriched for differences between 
control and docetaxel treated OCSCs, further supporting all previous findings that docetaxel does 
not affect OCSC metabolism over a 48 hour period.  
3.2.4. Glucose deprivation, hypoxia, and ischemia affect OCC and OCSCs in 
a time-dependent manner 
GCxGC-MS analysis was used to profile the metabolism of the OCCs and OCSCs over the 48 
hour period. For OCCs, 98 intracellular analytes were reproducibly detected with 35 of these 
analytes annotated to unique metabolites. For OCSCs, 81 reproducibly measured intracellular 
analytes were detected with 32 annotated to unique metabolites.  
Two-way ANOVA was used to analyze the data to account for changes as a function of both 
time and treatment. OCC and OCSC samples were analyzed with all conditions together, and 
with each of the conditions individually compared against the normal condition. The number of 
analytes with statistically significant effects indicated by these analyses (FDR < 0.05) is shown 
in Table 3.5.  
Table 3.5: Number of statistically significant analytes for OCCs and OCSCs using two-way 
ANOVA. 
  
All Analytes Metabolites 
  





All Conditions 40 69 45 14 22 12 
Glucose Deprived 
vs Control 14 49 20 1 15 5 
Hypoxic vs Control 23 52 23 7 15 4 






All Conditions 21 52 27 7 19 5 
Glucose Deprived 
vs Control 11 33 17 3 14 5 
Hypoxic vs Control 4 34 9 0 10 2 




Individual annotated metabolites found to have statistically significant group effects for all 
conditions or for any individual condition are shown in Figure 3.2 for OCCs and OCSCs. Five 
metabolites had significant group effects for both OCCs and OCSCs when including all 
conditions, representing a core of conserved metabolites with a major role in responding to one 
or more of these environmental stressors. One of these metabolites, phosphoethanolamine, is a 
substrate for many cell membrane phospholipids that has recently been shown to induce both cell 
cycle arrest and apoptosis in cancer cells.12, 13 Here, intracellular phosphoethanolamine levels for 
both OCCs and OCSCs stay fairly consistent over 48 hours for the control cells, but for the 
metabolic perturbations, the levels steadily increase over 48 hours. Because the 
phosphoethanolamine levels increase slightly but consistently for all metabolic perturbations, the 
reaction seems to be a generalized metabolic stress response. This reaction could be indicative of 
increased phospholipid membrane turnover or an apoptotic response to the increasing stress 
levels. Thus far, the apoptotic effects of phosphoethanolamine have only been studied in a 
controlled dose manner;12, 13 it would be interesting to determine if the cells themselves use 




Figure 3.2: Environmental perturbations cause different metabolite-level changes in OCCs and 
OCSCs. Heatmap displays false discovery rate corrected p values for OCC and OCSC group effects for 
different metabolites during two-way ANOVA. Metabolites are shown in the rows, with the conditions 
represented in the columns. The darker the blue, the more statistically significantly different the 
metabolite differences are between the stated condition and the control. The five metabolites at the top 
represent a core, conserved set of metabolites with overall significance in both cell types.  
Other types of stress-responsive analytes are also evident in this analysis. For example, there are 
numerous analytes that would not have been detectable as having significant group effects 
without the combination of all of the metabolic perturbations studied herein. This group, which 
includes 4-hydroxy-L-proline, GABA, and threonine for OCCs, can be seen as a “weak core 
response”: not like the strong, individually significant core response observed for mannose-6-
phosphate across all perturbations for OCCs, but nonetheless consistent in its small effect across 
all perturbations so as to yield an overall significant effect.  
3.2.5. PCA shows separation between environmental perturbations for both 
OCCs and OCSCs 
To assess the differences between cell types for the perturbations, PCA was used to examine the 
results of each perturbation individually, for OCCs and OCSCs together. Again, analytes whose 
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differences were due to the differences in media or extraction method were removed as discussed 
in the methods. PCA revealed separation between OCCs and OCSCs for each individual 
condition as shown in Figure 3.3, with the hypoxic perturbation showing the most distinct 
separation between the cell types. PC1 and PC2 are both responsible for separation of the OCC 
and OCSC samples as well as time point separation in different perturbations. For the control, 
the analytes most responsible for separation between OCCs and OCSCs are unknowns, myristic 
acid, and threonine. Unknowns, threonine, tyrosine, leucine, and valine are the analytes 
important for separation in glucose deprivation. The analytes most important for hypoxic 
separation are unknowns, 3,8-dimethylundecane, and ribose. Unknowns, n-dodecane, 4,6-
dimethyldodecane, and 2,3,5,8-tetramethyl-decane are the most important analytes for separation 
between OCCs and OCSCs in ischemia. It is clear that both hypoxia and ischemia amplify the 
differences between OCCs and OCSCs evident in the normoxic condition; the effects of glucose 





Figure 3.3: Control, glucose deprived, hypoxic, and ischemic conditions show varying effects on the 
differences between the two cell types. PCA of both cell types and all time points for four 
environmental conditions captured varying separation between OCCs and OCSCs. The greatest metabolic 
difference between the two cell types is during hypoxia; both hypoxia and ischemia amplify the 
differences between OCCs and OCSCs compared to control. PC1 and PC2 both capture separation 
between the cell types as well as time point separation in the different conditions. Dotted ovals represent 
95% confidence intervals of the membership of each sample class. 
To further characterize the effects of the perturbations on OCC and OCSC metabolism, PCA was 
performed on each cell type individually for all perturbations together. Plotting all conditions 
across all time points showed differences between the different conditions for both cell types, but 
only at later time points (data not shown). This suggests that the effects of these perturbations are 
not extremely fast, even though they are each tied closely to cellular metabolism; the impacts of 
these perturbations are best observed accumulated over days. For clarity and to facilitate 
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interpretation, time points at 2, 4, and 8 hours were removed from further visualizations and 
analyses, and PCA was performed for all conditions at 0, 24 and 48 hours, as seen in Figure 3.4.  
 
Figure 3.4: PCA for OCCs and OCSCs shows differences between environmental perturbations at 
later time points for each cell type. PCA shows separation between conditions and time points at later 
time points. In both cell types, PC1 plays a large role in separating time points, and PC2 captures 
variation between the conditions. Dotted ovals represent 95% confidence intervals of the membership of 
each sample class. A) Control samples show little temporal variation in OCCs. Effects of ischemia are not 
additive based on the effects of glucose deprivation and hypoxia individually at 48 hours, but are much 
more similar to the effects of glucose deprivation than they are to hypoxia. B) OCSC control samples 
display much greater temporal variation compared to OCCs. There is no metabolic distinction between 
control and hypoxic cells, and 48-hour ischemia samples again show non-additive effects compared to 
glucose-deprived and hypoxic conditions. 
For OCCs, shown in Figure 3.4A, PC1 plays a large role in separating the different time points, 
with hydroxyproline, threonine, and tyrosine being most important analytes for the separation. 
PC2 plays a large role in separating the treatment conditions, with unknown analytes causing 
most of the separation between conditions. The control and initial samples are more similar to 
each other than the other conditions based on their close clustering, showing that the applied 
perturbations induce significant changes in metabolism. The effects of ischemia, even though it 
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is a combination of the glucose deprived and hypoxic conditions, are not additive based on the 
effects of glucose deprivation and hypoxia individually; instead, the 48 hour time points 
experience much greater differences for ischemia than for either of the two individual treatments. 
The overall proximity of the ischemia treatment to the glucose deprivation suggests that the 
metabolic impacts of ischemia are driven more strongly by glucose deprivation than by hypoxia.  
PCA of OCSC samples again shows differences between conditions during the later time points, 
as seen in Figure 3.4B. PC1 captures significant time variance, with an unknown, phenylalanine, 
pyroglutamate, and tyrosine responsible for most of the variance. PC2 captures significant 
separation between the treatments, with 2,9-dimethyldecane, hexadecane, and cis-1,4-
dimethylcyclooctane most responsible for separation. Similar to the OCCs, glucose deprivation 
shifted the OCSCs’ metabolic profile away from the control, and ischemia showed a nonadditive 
extra effect on metabolism at 48 hours. Unlike OCCs, though, the control samples display 
substantial changes and variability between time points; this is to be expected based on previous 
work indicating temporal changes in metabolism of OCSCs.6 In addition, the hypoxic samples 
completely overlap the control, showing that hypoxia did not substantially alter the metabolic 
profile of the OCSCs from its normal state as it did to OCCs. Hypoxic conditions have been 
shown to support stemness within cancer stem cells in vitro and cancer stem cells have been 
located in hypoxic niches within the tumor.14, 15 Therefore, it is possible that OCSCs have 
adapted to hypoxic environments to the point where hypoxia no longer puts more stress on their 
metabolism compared to growth under normal oxygen concentrations.  
3.2.6. MPEA further supports that OCCs and OCSCs respond to hypoxia and 
glucose deprivation differently 
Using MPEA in MetaboAnalyst, 21 KEGG pathways for OCCs and 23 KEGG pathways for 
OCSCs were identified as being statistically significantly enriched (FDR < 0.05) in differences 
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between the normal, glucose deprived, hypoxic, and ischemic conditions across all time points. 
Figure 5 breaks the pathway responses into three categories: “strong core” responses in either 
cell type are significant for multiple individual conditions as well as all individual conditions 
together. “Weak core” responses are significant only for all conditions together, but never for 
any individual condition, suggesting the combination of many small, individually insignificant 
effects to reflect a significant core response. The remaining class of pathways are “perturbation-
specific” responses: they are significant for only one perturbation in a cell type, which may or 
may not drive overall significance for all conditions. Within these subtypes, we can then further 
identify which of these responses are conserved between cell types, and which are unique to cell 
types. 
Overall, 18 of the statistically significantly enriched pathways overlap between OCCs and 
OCSCs, indicating that many of the changes caused by the metabolic perturbations are similar 
between the two cells. However, 6 pathways were exclusively enriched in the OCCs and 5 
pathways were exclusive for OCSCs. Detailed investigation of why these pathways were only 
altered in one cell type during all the perturbations may help to further explain the differences in 




Figure 3.5: MPEA results show different trends in enriched pathways for OCCs, OCSCs, and both.  
Heatmap displays false discovery rate corrected p values for metabolite pathway enrichment analysis 
results for (A) OCCs, and (B) OCSCs. KEGG pathways are shown in the rows with the conditions 
represented in the columns. Strong core response pathways are those with significant enrichment in all 
conditions and in at least one individual condition; weak core response pathways are those enriched only 
in all conditions; perturbation specific pathways are those that are only enriched for a unique individual 
condition. The darker the blue, the more statistically significantly enriched the pathway is for metabolic 
differences. Grey boxes represent pathways with FDR > 0.05. All: glucose deprived vs hypoxia vs 
ischemia vs control; GlucDep: glucose deprived vs control; Hypoxia: hypoxia vs control; Ischemia: 
ischemia vs control. 
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To determine which pathways are most affected by each perturbation, each individual condition 
was compared against the control condition using MPEA. In OCCs, glucose deprivation resulted 
in only two pathways significantly enriched, amino sugar and nucleotide sugar metabolism and 
fructose and mannose metabolism pathways, both strong core responses. Therefore, it appears 
that glucose deprivation in OCCs only directly affects sugar metabolism pathways and the cells 
adjust their metabolism to meet their energy and other requirements without systems-scale 
metabolic impact. In contrast, glucose deprivation resulted in 14 significantly enriched pathways 
in OCSCs that are widespread throughout metabolism, including amino acid metabolism, 
carbohydrate metabolism, lipid metabolism, and cofactor and vitamin metabolism. The 
differences in lipid metabolism pathways, glycerophospholipid metabolism and sphingolipid 
metabolism, are largely driven by differences in phosphoethanolamine levels between the control 
and glucose deprived cells, discussed previously. Overall, these findings suggest that OCSCs 
might be more dependent on glucose than OCCs, since glucose deprivation has a much larger 
effect on OCSC metabolism than OCC metabolism. This is particularly surprising given the 
substantially lower proliferation rate of OCSCs and the known significant glycolytic flux of the 
Warburg effect in bulk cancer cells. 
Under hypoxic conditions, 12 pathways were significantly enriched for metabolic differences for 
OCCs. Out of these 12, two pathways were perturbation-specific responses, phenylalanine 
metabolism and phenylalanine, tyrosine and tryptophan biosynthesis, both of which are amino 
acid metabolism pathways. Tyrosine and phenylalanine are the metabolites most responsible for 
the differences in these two pathways, both of which have lower levels in hypoxic conditions. 
Along with these two pathways, there are three other amino acid metabolism pathways enriched 
for statistically significant differences along with aminoacyl-tRNA biosynthesis, which prepares 
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for translation. In all of these pathways, the amino acids driving the differences have lower levels 
in hypoxia than the control. Therefore, hypoxic conditions seem to be causing significant overall 
changes in amino acid metabolism, whether via decreased production or increased consumption. 
Hypoxia also has an observable effect on sulfur metabolism; the sulfur metabolism pathway 
supplies sulfur for cysteine and methionine metabolism, both of which are enriched for 
metabolites with lower levels in hypoxia. The only metabolites with higher levels in hypoxia are 
citric acid and malic acid, both of which play a major role in the TCA cycle. For OCSCs, in 
contrast, hypoxia only resulted in one pathway being significantly enriched (glyoxylate and 
dicarboxylate metabolism), thus reinforcing the idea that OCSCs have fairly completely adapted 
to a hypoxic environment. 
Ischemia caused 16 pathways to be significantly enriched for metabolic differences for the 
OCCs, ten of which are perturbation-specific responses (though nine of them drive significance 
in the overall analysis as well). For OCSCs, 15 pathways were statistically significantly enriched. 
9 of these pathways are in common between the two cell types, showing a surprisingly well-
conserved ischemia response conserved between the two cell types, especially considering that 
the responses to hypoxia and glucose deprivation alone are not at all conserved, being very cell 
type-specific. Interestingly, for both cells there are some metabolic pathways that are enriched 
for differences under glucose deprived or hypoxic conditions that are not seen under ischemic 
conditions, which suggests that the effect ischemia has on the cells is not an additive affect of 
glucose deprivation and hypoxia.  
Overall, OCCs and OCSCs have different trends in pathway response to the environmental 
perturbations, but do display some level of conservation. The conserved strong core response 
module consists of amino sugar and nucleotide sugar metabolism and fructose and mannose 
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metabolism, which are in the strong core modules of both cell types. The conserved core 
response module can be broadened to also include cysteine and methionine metabolism; glycine, 
serine, and threonine metabolism; and pyruvate metabolism. Each of these display strong core 
responses across the perturbations in one cell type and weak core responses across the 
perturbations in the other cell type. These five pathways are the ones that the two cell types use 
very similarly in responding to these environmental stresses, representing a core, conserved 
response between the cell types. This leaves three (weak or strong) core responses in OCCs and 
thirteen (weak or strong) core responses in OCSCs as the cell type-specific core responses; many 
of these core responses pathways in one cell type may be perturbation-specific in the other, 
though some (for example, tyrosine metabolism) are core in one but not at all significant in the 
other. Taken together, though, the set of core responses is much larger in OCSCs, indicating that 
OCSCs are responding more similarly to the different environmental perturbations while OCCs 
are dominated by more perturbation-specific responses. 
3.2.7. Limitations 
For this work, only one isogenic cancer cell and cancer stem cell line pair was used. Therefore, 
the results found here only correspond to differences between these two particular ovarian cancer 
cell lines. It would be desirable to expand this study to other isogenic cancer cell and cancer stem 
cell line pairs, but, unfortunately, there are very few such cell lines, and they are not easily 
obtainable. As such cell line pairs become more widely available, these metabolic experiments 
should be expanded to additional cell lines to determine if the results shown here are 
characteristic of this specific isogenic pair or if they are indicative of broader isogenic (ovarian) 
cancer cell and cancer stem cell line differences. 
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Another limitation of this study is the constraint of biological interpretation due to metabolite 
identification. Over half of the analytes that are retained in the final data set are labeled as 
unknown analytes, due to low match scores during our conservative metabolite identification 
step during processing. Additionally, the database used for metabolite pathway enrichment 
analysis does not include all of the metabolites identified within our data set. Therefore, there 
may be additional changes, especially in the metabolite pathway enrichment analysis, that are not 
currently detected because of lack of metabolite identification. Greater efforts must be made 
toward increasing the number of metabolites available within these databases in order for a 
complete understanding of the changes detected in these experiments. And, as previously noted, 
even conservative annotation score thresholds can yield false identifications on occasion. 
Finally, our chemotherapeutic perturbation was only applied under normal cell culture 
conditions, which, as discussed for metformin, can cause different results than what would be 
seen under tumor conditions. To further explore the metabolic changes caused by 
chemotherapeutics, future work will include applying chemotherapeutic and environmental 
perturbations at the same time. 
3.3. Conclusions 
In this study, OCC and OCSC were shown to have different metabolic reactions to biologically 
based perturbations applied in vitro to mimic in vivo tumor conditions. Docetaxel treatment did 
not affect the metabolism of OCSCs, showing that these cells are chemo-resistant even on a 
metabolic level. Docetaxel had a substantial effect on OCCs, especially in amino acid 
metabolism and carbohydrate metabolism. Docetaxel also caused increased levels of uracil 
compared to the control, which may help explain why treatment with competitive inhibitors of 
uracil in conjunction with docetaxel improves tumor treatment. OCCs and OCSCs also reacted 
 
 85 
differently to glucose deprivation, hypoxia, and ischemia perturbations. Glucose deprivation 
alone did not have a large affect on OCC metabolism, but did perturb many pathways in the 
OCSCs, a surprising result based on the relative proliferation rates of the cells and the known 
high glycolytic flux associated with the Warburg effect and cancerous proliferation. Hypoxia had 
the reverse affect, affecting the metabolism of OCCs but not OCSCs, likely indicative of the 
ability of hypoxic conditions to support CSC stemness in vivo. Ischemia affected the metabolism 
of both cell types in many of the same pathways, suggesting that OCCs and OCSCs respond to 
this stress in a similar way. However, the ischemia response in both cells is not simply an 
additive response of the glucose deprivation and hypoxia conditions, especially since one of 
those conditions essentially yielded no response in each cell type.  Both pathway-level analysis 
and metabolite-level analyses helped to identify core metabolic responses to multiple 
perturbations common across both cell types, including an increase in phosphoethanolamine 
levels for all perturbations for both cell types as a generic stress response. Five metabolic 
pathways were identified as a conserved core response module, responding to multiple 
environmental perturbations in each cell type. Overall, these metabolic differences seen during 
chemotherapeutic and environmental perturbations in vitro help to provide much-needed detail to 
characterize the inherent differences in metabolism between OCCs and OCSCs; this information 
could potentially be used in the development of targeted treatments against OCSCs. 
3.4. Methods 
3.4.1. Cell culture 
The OVCAR-3 cell line was obtained from the Developmental Therapeutic Program (DTP) of 
the National Cancer Institute (NCI). The OVCAR-3 ovarian cancer cells (OCCs) were cultured 
in R10 medium: RPMI-1640 (Cellgro, Mediatech Inc., Manassas, VA) supplemented with 10% 
fetal bovine serum (FBS, Invitrogen, Grand Island, NY) and 1% antibiotic-antimycotic solution 
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(Cellgro, Mediatech Inc., Manassas, VA). Authenticity of the OVCAR-3 cell line was confirmed 
using short tandem repeat profiling performed by IDEXX RADIL (Columbia, MO) in October 
2013. Cells were grown until confluence and subcultured at a ratio of 1:4. 
Ovarian cancer stem cells (OCSCs) were previously derived from a side population of OVCAR-
3. OCSCs are less adherent than OVCAR-3 cells and, unlike OVCAR-3 cells that are grown as 
adherent monolayers, are grown as spheroids in stem cell media to help support their stemness as 
previously described.11 Briefly, the OCSCs were cultured in ultra-low attachment petri dishes 
(Corning Incorporated, Corning, NY) in stem cell medium: DMEM/F12 (1:1) (Cellgro, 
Mediatech Inc., Manassas, VA) supplemented with 0.4% bovine serum albumin (BSA, Sigma-
Aldrich, St. Louis, MO), 20 ng/mL epidermal growth factor (EGF, Invitrogen, Grand Island, 
NY), 10 ng/mL basic fibroblast growth factor (bFGF, Sigma-Aldrich, St. Louis, MO), 5 µg/mL 
insulin (Sigma-Aldrich, St. Louis, MO), and 1% antibiotic-antimycotic solution (Cellgro, 
Mediatech Inc., Manassas, VA). The spheroids were dissociated and reseeded at a density of 105 
cells/mL each week.  
3.4.2. Environmental perturbation experiments 
There were four environmental perturbations used in these experiments: chemotherapeutic, 
glucose deprived, hypoxia, and ischemia. According to the American Cancer Society, the 
common first line chemotherapeutic treatment for ovarian cancer is a combination of a platinum 
compound, like cisplatin, and a taxane compound, such as docetaxel. Docetaxel was chosen as 
the chemotherapeutic treatment because it interrupts cellular division and thus would more likely 
have a direct effect on metabolism over cisplatin, which causes DNA crosslinking. Docetaxel 
disrupts cellular division through suppression of microtubule dynamics in the cells, which 
eventually leads to apoptosis.16 For OCCs, two different concentrations of docetaxel dissolved in 
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dimethylsulfoxide (DMSO) were given to the cells, the IC50 value (10nM) and 50% above the 
IC50 value (1.5x IC50) (15nM). IC50 values for OCCs were reported in previous work.
11 For the 
OCSCs, only the higher concentration of docetaxel (1.5x IC50 of the OCCs) was given to the 
cells since the higher concentration would be more likely to have an impact on the OCSCs. 
Solutions of docetaxel dissolved in DMSO at 100μM and 150μM were used to obtain the desired 
final required concentrations for IC50 and 1.5x IC50. An equivalent amount of DMSO was added 
to control media to account for effects of DMSO. 
For glucose-deprived conditions, RPMI-1640 (Cellgro, Mediatech Inc., Manassas, VA) and 
DMEM-F12 (US Biological, Massachusetts, MA) without glucose were obtained and used to 
make glucose-free R10 and stem cell media as described above. For hypoxic conditions, cells 
were placed in a hypoxic chamber with 2% oxygen at the beginning of the experiment. Ischemic 
conditions were a combination of glucose deprived and hypoxic conditions. 
Immediately before applying the environmental perturbations, OCCs were passaged and seeded 
in 6-well plates (Greiner Bio-One, Monroe, NC) with a well surface area of 6.9 cm2 at a density 
of 3x105 cells/well in 2mL of R10 medium and incubated for 24 hours to allow the cells to attach 
and recover. The medium was then removed, wells were washed once with PBS, and then 2mL 
of fresh experimental medium (prepared as described above) was applied to begin the 
experiment. OCSCs were dissociated and seeded into ultra-low attachment 6-well plates 
(Corning Incorporated, Corning, NY) containing 2mL of fresh experimental stem cell medium 
(prepared as described above) at a density of 3x105 cells/well with a well surface area of 6.9 cm2. 
Both the OCC and OCSC experiments were performed in biological triplicate. 
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3.4.3. Sampling protocols 
For the chemotherapeutic perturbation, samples were taken at 0 minutes, 24 hours, and 48 hours. 
For the hypoxic and glucose deprived perturbation, samples were taken at 0 minutes, 2 hours, 4 
hours, 8 hours, 24 hours, and 48 hours. The additional short-term time points were taken since 
the direct metabolic nature of the perturbations might cause a fairly rapid metabolic response. 
For OCCs, medium was removed and cells were quickly washed with 1mL PBS at 37°C, which 
was aspirated off, and then 700 µL of 80:20 methanol/water solution at -80°C was added 
immediately. The plate was then incubated at -80°C for 15 minutes. After incubation, remaining 
cellular debris were harvested using a cell scraper (BD Falcon, San Jose, CA) for intracellular 
analysis. For OCSCs, the media-cell mixture was transferred to a filter cup (Microcheck II 
beverage monitor, Pall, Port Washington, NY) with a pre-wetted membrane (0.45 µm pore 
Express PLUS Polyethersulfone membrane, Millipore, Billerica, MA) and the medium was 
filtered from the cells. The cells were then quickly washed with 4mL PBS at 37°C. The filter was 
then removed and placed upside down in a petri dish containing 1.5mL of 80:20 methanol/water 
solution at -80°C. The samples were then incubated at -80°C for 15 minutes. After 15 minutes, 
the petri dish was removed and the filter was flipped over and washed using the 1.5mL 80:20 
methanol/water solution to remove any debris still caught in the filter. An extraction blank was 
made for the OCSCs following the same procedure above but only 4mL PBS was washed 
through the filter. 
For both cell types, the intracellular solution was then transferred to a microcentrifuge tube in a 
cold ethanol bath and centrifuged at 5,000 g for 5 minutes at -4°C. The supernatant was retained, 
and the pellet was subsequently re-extracted twice in 100 µL of the cold 80:20 methanol/water 
solution, with all supernatants being pooled.17 Intracellular and extracellular samples were stored 
at -80°C and -20°C, respectively, until analysis. 
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3.4.4. Growth media experiment 
To control for the differences in media between the two cell types, a secondary experiment was 
performed where OCCs were grown in parallel in R10 media and stem cell media for 48 hours. 
Intracellular samples were taken at 0, 24, and 48 hours in the same manner as described above 
for the OCCs. Cell counts were also taken (data not shown) and showed that OCCs grow slower 
in the OCSC medium than they do in their normal medium, mimicking the slower growth rate of 
OCSCs.  
3.4.5. GCxGC-MS analysis 
Before derivatization, intracellular samples were vacuum concentrated in a CentriVap at 40°C 
until completely dry. The volume that was vacuum concentrated was varied for each sample in 
order to yield a final concentration of 3x103 live cell equivalents/µL after derivatization, based 
on the cell density at the sample time. The samples were derivatized following the protocol laid 
out by Fiehn, et. al.18 Briefly, 2.5 µL of 40 mg/mL O-methylhydroxylamine hydrochloride (MP 
Biomedicals, LLC, Santa Ana, CA) in pyridine was added to the dried sample and shaken at 
1400 rpm for 90 minutes at 30°C. 22.5 µL of N-methyl-N-(trimethylsilyl) trifluoroacetamide 
(MSTFA) + 1% trimethylchlorosilane (TMCS) (Thermo Scientific, Lafayette, CO) was then 
added to the samples which were then shaken at 1400 rpm for 30 minutes at 37°C. Samples were 
centrifuged at 21,100 g for 3 minutes and 10 µL of the supernatant was added to an autosampler 
vial. Samples were spiked with 0.10 µL of a retention time standard solution consisting of fatty 
acid methyl esters (FAMEs) and an internal standard of nonadecanoic acid methyl ester 
dissolved in dimethylformamide. 
A LECO Pegasus 4D instrument with an Aglient 7683B autosampler, Agilent 7890A gas 
chromatograph and time-of-flight mass spectrometer (TOF-MS) was used to analyze the 
samples. The first column was an HP-5, 30 m long x 0.320 mm ID x 0.25 µm film thickness 
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(Agilent, Santa Clara, CA), and the second was an Rtx-200, 2 m long x 0.25 mm ID x 0.25 µm 
film thickness (Restek, Bellefonte, PA). Specific autosampler, gas chromatography, and mass 
spectrometry methods can be found in Appendix A. 
3.4.6. Data analysis 
Sample runs were first analyzed in ChromaTOF (LECO, St. Joseph, MI) to determine baseline, 
peak area, and peak identification. Briefly, settings included a baseline offset of 0.5, automatic 
smoothing, 1st dimension peak width of 24 seconds, 2nd dimension peak width of 0.10 seconds, 
and a match of 700 required to combine peaks with a minimum signal-to-noise (S/N) of 5 for all 
subpeaks. Peaks were required to have a S/N of 10 and have a minimum similarity score of 800 
before assigning a name. Unique mass was used for area and height calculation.  
To align the samples, MetPP (http://metaopen.sourceforge.net/metpp.html) was used.19 Sample 
files and a derivatization reagent blank file were uploaded from ChromaTOF. Unknowns were 
retained during the peak alignment process. The derivatization reagent blank file for OCCs or the 
extraction blank file for OCSCs was used to subtract peaks attributable only to sample 
preparation reagents from the corresponding cells’ sample files. On-the-fly alignment was used 
with quality control samples manually selected as the peak list for primary alignment. Peak 
alignment was performed using the default criteria. This was done for the OCC data only, 
OCSCs only, and the combined OCC and OCSC data set for both metabolic perturbation 
experiments. For the combined OCC and OCSC data sets, blank peaks were not deducted during 
alignment; instead they were aligned with the metabolite samples for later removal. 
After alignment, further processing of the data was done based on the procedure laid out by 
Dunn, et. al.20 Batch effects were removed from the intracellular data set using LOESS. To 
remove analytes that were not reproducibly detected, analytes for which more than half of the 
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values were missing in the QC samples or for which the QC samples had a coefficient of 
variance larger than 0.5 were removed from the data set. Then, missing values were manually 
corrected using small value correction only if all the values were missing in the biological 
replicate. Annotated analytes were then compared to the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) or the Human Metabolome Database (HMDB); if they were listed in KEGG 
or HMDB they were identified as metabolites. The metabolites were then verified by a manual 
confirmation of similarity between the annotated peak spectrum and the library spectrum. 
Manual confirmation resulted in tetrahydrofuran and pyruvaldehyde peaks re-annotated from 
metabolite peaks to unknown peaks. 
Finally, MetaboAnalyst (http://metaboanalyst.ca/) was used for statistical and enrichment 
analysis, applying both the statistical analysis and time series analysis modules.21 For both 
analyses, remaining missing values were k-nearest neighbors (KNN) corrected. Data was filtered 
using the interquantile range method and then log-transformed using generalized logarithm 
transformation (base 2) and autoscaled.  
For enrichment analysis, both metabolite set enrichment analysis (MSEA) and metabolite 
pathway enrichment analysis (MPEA) yielded similar results, so only MPEA results were 
considered further. The entire time series was uploaded as discrete data with compound names. 
Metabolites were properly matched to their HMDB codes before processing the data. Data 
processing followed the same steps as listed above for missing value imputation and data 
normalization. The Homo sapiens pathway library was used for analysis and an in-house 
metabolite reference library based on detectable metabolites for our system was uploaded. 
Global test was used for pathway enrichment analysis, with relative-betweeness centrality as the 
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pathway topology analysis. Pathways with an FDR < 0.05 were considered significantly 
enriched.  
3.4.7. Removal of media and extraction effects 
For the combined OCC and OCSC data sets only, differences potentially due to media effects 
and extraction methods were removed. To specifically identify media effects, MetaboAnalyst 
was first used to analyze the OCC media control samples. Any analytes found to have 
statistically significant differences (t-test, all time points, FDR < 0.05) between the OCCs grown 
in R10 and OCCs grown in stem cell media were then removed from the combined data set to 
eliminate metabolic changes due to media differences.  
The different extraction methods for the OCCs and OCSCs resulted in systematic differences 
because of analytes extracted from the filter used for OCSCs. To identify differences due to 
extraction methods, the derivatization reagent blanks and filter extraction blanks were analyzed 
in MetaboAnalyst. Again, any analytes found to have statistically significant differences (t-test, 
FDR < 0.05) between the two blanks were removed from the combined OCC and OCSC data set. 
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Chapter 4 Metabolic changes during mesenchymal to epithelial 
transition 
4.1. Introduction 
The epithelial to mesenchymal transition (EMT) is an important process in embryonic 
development, allowing the epithelial phenotype cells to transition to a mesenchymal phenotype 
in order to populate all the developing tissues in the embryo.1 Epithelial cells have a block-like 
shape and have tight cell-to-cell junctions, some of which are formed by cadherin 
transmembrane proteins such as E-cadherin. Mesenchymal cells have an elongated spindle shape 
and are more mobile than epithelial cells; they do not form cell-to-cell junctions. Recent cancer 
research has led many to believe that the EMT process is being utilized by tumors for 
metastasis.2  
EMT is triggered in the primary tumor through interactions with the tumor microenvironment. 
Signaling from the stroma cells can induce tumor cells to produce transcription factors that 
trigger EMT.2 After undergoing EMT, the new mesenchymal cells can migrate away from the 
tumor and throughout the body. Upon reaching a potential metastatic site, the cells undergo the 
reverse process, mesenchymal to epithelial transition (MET), and form a metastatic lesion. 
Forming a new metastatic lesion is not straightforward, as the cells have to adhere and grow in 
an unfamiliar and usually unwelcoming environment. Recent research into EMT provides a 
hypothesis of how cancer cells overcome this hurdle: EMT can give stem-like properties to the 
cancer cells.3, 4 It has been shown that after undergoing EMT, cells obtain stem-like properties, 
such as stem cell markers, the ability to form spheres in culture, and chemoresistance.5-7 This 
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evidence suggests that EMT allows for the metastatic event and gives the cancer cells the 
properties necessary to successfully form a metastatic lesion.   
There has been no clinical evidence cancer cells undergoing the EMT-MET process for 
metastasis, but many groups have been able to model one or both of the transitions. EMT is 
usually induced in one of two ways: expression of transcription factors or through microRNA 
transfection. Research into microRNAs has shown that they are important regulators of EMT, 
since many target transcription factors that have been identified as playing a role in EMT.8-12 
Representative examples of these transcription factors include ZEB, Snail, Slug, Twist, which 
are responsible for regulating many different cellular pathways, but all commonly repress 
epithelial markers, such as E-cadherin, to facilitate EMT.13-15 
The McDonald group was able to induce and sustain MET by transfecting HEY cells with a 
microRNA, miR-429.16 Based on their results, a larger study was designed where 
transcriptomics, metabolomics, microRNA and protein measurements were all taken at identical 
time points during the process, tracking multiple omic-level changes in the cell. The experiment 
was designed to allow for an initial MET, followed by EMT. The cells were transfected initially 
with miR-429 to induce MET, and then with no other transfection to sustain the levels of miR-
429, the cells subsequently underwent EMT during the latter part of the experiment. Presented 
here are the results of the metabolomics analysis of the experiment. 
4.2. Results & Discussion 
4.2.1. Mesenchymal to epithelial transition causes changes in phenotype and 
known mesenchymal and epithelial biomarkers 
HEY cells were transfected with either miR-429 to induce MET or a control scrambled 
microRNA, specifically designed to avoid targeting any known microRNA binding sites. HEY 
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cells were initially transfected and then profiled over a period of 144 hours. After a period of 48 
hours, clear morphological differences were noticed between miR-429 transfected and control 
cells, as shown in Figure 4.1. Control cells still had their original mesenchymal morphology, 
while miR-429 transfected cells had transitioned into an epithelial morphology. After a period of 
144 hours, both miR-429 and control cells displayed their original mesenchymal morphology, as 
shown in Figure 4.1. During the experiment, known markers of MET were profiled and 
displayed changes correlating with a MET to EMT during the 144 hour period (data not shown). 
These phenotypic changes, along with morphological and supporting transcriptomic data, 
indicate that the HEY cells did undergo a MET and then a corresponding EMT. 
 
Figure 4.1: miR-429 transfected cells shift from a mesenchymal to epithelial back to mesenchymal 
morphology over the experimental time period. Untransfected HEY cells show the typical 
mesenchymal morphology with elongated spindles. Once transfected with miR-429, the HEY cells 
exhibit a shift towards an epithelial morphology, with the most cells exhibiting the morphology at 48 
hours. After 48 hours, the cells show a clear shift back to mesenchymal morphology, with the change 
complete at 144 hours. Control transfected cells do not show a noticeable morphological change over the 
experimental time frame. 
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4.2.2. Metabolic profiling of MET 
To capture both the immediate and late term effects of miR-429 transfection on the metabolome, 
a collection of early and late time points were taken. The early time points were expected to 
capture any changes that occurred due to the transfection and were taken at 0, 3, 5, and 7 hours. 
The late time points were designed to capture metabolic changes in response to MET and were 
taken at 24, 48, 72, and 144 hours. Both intracellular and extracellular samples were taken at 
each time point in biological triplicate for both the miR-429 and scrambled microRNA 
conditions. All the samples were then run on a two-dimensional gas chromatograph – mass 
spectrometer (GCxGC-MS). After initial analysis, it was discovered that two of the three 
intracellular 24 hour time point control samples were identified as outliers both during the 
alignment step as well as during initial principal components analysis. Therefore, the 
intracellular 24 hour time points were removed from subsequent analysis. As all the samples for 
this experiment were the same cell type, differences due to cells grown in different media were 
not an issue as they were in Chapter 2 and Chapter 3. Therefore, results gained from extracellular 
samples are valid. 
4.2.2.1. Univariate analysis across all time points does not reveal consistent 
differences between control and miR-429 transfected cells 
Overall, 253 intracellular and 252 extracellular analytes were detected and aligned across all the 
samples (see Methods for details on detection and alignment). These analytes included unknown 
and identified (annotated) analytes, as well as metabolites. (In this paper, analytes that are 
identified in the Human Metabolite Database (HMDB) or in the Kyoto Encyclopedia of Genes 
and Genomes (KEGG) database are referred to as metabolites.) After removal of unknown and 
annotated analytes not associated with HMDB or KEGG, there were 63 unique intracellular and 
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82 unique extracellular metabolites. Initial analysis of the control and miR-429 transfected cells 
showed that neither the intracellular nor extracellular samples exhibited large changes across all 
the time points. For the intracellular samples, there was only one analyte, heptacosane, that had a 
statistically significant difference (FDR-corrected p-value of 0.022) between control and miR-
429 transfected cells across all the time points. For the extracellular samples, again there was 
only one metabolite, glucaric acid, that had a statistically significant difference (FDR-corrected 
p-value of 1.47x10-5) between control and miR-429 transfected cells across all the time points.  
This lack of difference between the control and miR-429 transfected cells was expected when all 
time points were included in the analysis since the HEY cells started out as a mesenchymal 
phenotype, then transitioned to an epithelial phenotype, and finally moved back to a 
mesenchymal phenotype. Therefore, if metabolism does change with MET, there should not be a 
consistent metabolic difference across the entire set of time points. Instead, a metabolic change is 
expected to be observable within a short time window wherein analysis should reveal a distinct 
difference between the control and miR-429 transfected cells. 
4.2.2.2. PCA shows intracellular metabolic differences at 72 hours due to MET-EMT 
Since a consistent metabolic change across all time points was not seen (or expected) in 
univariate analysis, the intracellular and extracellular data sets of annotated and unknown 
compounds were analyzed with principal component analysis (PCA). PCA allows for a graphical 
interpretation of the data and would therefore show cases were single time points exhibited 
differences between the control and miR-429 transfected cells. Again, analyzing the entire 
dataset across all time points, neither the intracellular nor extracellular data showed a difference 
between the control and miR-429 transfected conditions, as shown in Figure 4.2. Even though 
there was no difference between control and miR-429 transfected cells, distinct separation was 
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observed between early and late time points, as seen in Figure 4.3. This indicates that the time 
from the start to the finish of this experiment caused a larger variation in the metabolic data than 
did the transfection.  
 
Figure 4.2: Principal components analysis shows no difference between control and miR-429 
transfected samples. (A) PCA of intracellular samples shows no difference between control, initial, and 
miR-429 transfected cells. (B) PCA of extracellular samples shows no difference between control, initial, 




Figure 4.3: Principal components analysis shows clear difference between early and late time point 
samples. (A) Intracellular metabolomics data shows clear separation between late and early time point 
samples. (B) Late and early time points group together in the extracellular samples, but the distinction is 
not as clear as in the intracellular samples. 
To further break down the datasets into individual time points and to help remove some of the 
time variation, the intracellular and extracellular matrices were split into early and late time 
points and PCA was performed on each group separately. For the earlier time points, Figure 4.4, 
neither the intracellular nor extracellular samples show separation between time points or control 
and miR-429 transfected cells. Therefore, it is likely that no substantial metabolic changes occur 
in either the intracellular or extracellular samples from the beginning of the experiment through 
seven hours. 
The later time points, shown in Figure 4.5, exhibit clear separation by time point. In the 
intracellular samples (Figure 4.5A), separation was observed clearly by time point but this 
separation was also seen for the controls, suggesting the changes were not associated with MET. 
However, at 72 hours there is some separation seen between the control and miR-429 transfected 
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cells. The extracellular samples (Figure 4.5B) showed no separation by condition, but did 
suggest a trend of time point dependence on PC 1. Overall, most of the observed metabolic 
changes are likely due to changes in cellular growth, but small changes contributed to MET-
EMT may occur intracellularly at 72 hours. The same results were seen using the annotated 
metabolite-only intracellular and extracellular data sets. 
 
Figure 4.4: PCA shows no separation between time points for early time points only. Neither 
intracellular (A) nor extracellular (B) samples show only clear separation between time points or miR-429 




Figure 4.5: PCA shows some separation between time points for late time points only. Intracellular 
samples (A) show a clear separation between time points, but only separation between control and miR-
429 transfected cells at 72 hours. Extracellular samples (B) show no difference between either time points 
or control and miR-429 transfected cells. 
4.2.2.3. Time series analysis reveals a MET-EMT metabolic hysteresis effect  
To further explore the MET-EMT differences seen intracellularly at 72 hours, two different 
analysis techniques were used to analyze the samples in a time-based manner. First, two-way 
ANOVA was used in MetaboAnalyst time series analysis, which takes greater advantage of the 
time series nature of the experiment. Two-way ANOVA uses a linear regression model to 
separate out effects based on group (miR-429 vs control), time, and interaction variables. 
Statistical values are assigned to the variables and are shown in Table 4.1 for intracellular and 
extracellular samples. Two-way ANOVA was performed on both the unknown and annotated 
compounds data set and the metabolite only data set. Most of the analytes with statistically 
significant values fall into the time variable, meaning that the analyte has a very similar time 
trend between control and miR-429 transfected cells. However, there are a few analytes for both 
the intracellular and extracellular samples that show statistically significant differences between 
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the control and miR-429 transfected cells. The metabolites that are statistically significantly 
different in the group category are listed in Table 4.1. The intracellular metabolites that differ 
between miR-429 and control transfected cells are all different classes, suggesting that miR-429 
induced MET-EMT is not affecting a specific metabolism pathway, but instead slightly perturbs 
many different metabolites. The same holds true for the extracellular metabolites.  
Table 4.1: Time series analysis results from two-way ANOVA. Number of analytes with a FDR 
corrected p value < 0.05 from time series analysis for intracellular and extracellular samples. The group 
term captures differences between control and miR-429 transfected cells; time term captures similarity 




All Analytes Metabolites All Analytes Metabolites 
Group 26 7 21 9 
Time 143 46 101 39 
Interaction 41 10 29 9 
 
Table 4.2: Metabolites identified as statistically significantly different for the group category using 
two-way ANOVA. 
Metabolites Group Time Interaction 
Intracellular 
6-Phosphogluconic acid 1.05E-03 3.54E-19 5.45E-15 
Pyroglutamic acid 1.05E-03 4.63E-15 1.41E-11 
L-Malic acid 1.05E-03 9.49E-14 1.59E-12 
L-Arginine 1.61E-03 4.45E-12 9.65E-07 
2-Methylbenzoic acid 5.96E-03 4.65E-18 5.45E-15 
Uridine 5'-monophosphate 0.0222 2.20E-15 3.28E-06 
N-Decane 0.0427 0.2618 0.7521 
Extracellular 
L-Serine 1.39E-04 3.06E-27 1.25E-26 
Pentadecane 1.39E-04 1.30E-21 2.29E-21 
Carbodiimide 4.94E-04 8.07E-19 3.41E-17 
D-Psicose 5.26E-04 1.63E-19 2.71E-19 
L-Lactic acid 3.78E-03 5.43E-19 2.84E-18 
Pyridoxine 5.08E-03 9.20E-21 1.20E-17 
Methanol 5.62E-03 9.76E-23 2.37E-13 
Serotonin 9.39E-03 9.76E-23 1.96E-13 




Delving further, each time point was individually analyzed through t-test and fold change 
analysis to determine differences between control and miR-429 transfected cells. This was done 
for both the intracellular and extracellular samples. Unsurprisingly, no statistically significant 
differences were detected between the control and miR-429 transfected cells in any of the early 
time points (0, 3, 5, and 7 hours) either in the intracellular or extracellular samples. Interestingly 
though, when looking at the later time points, there are a small number of metabolites that are 
consistently different between control and miR-429 transfected cells at both 72 and 144 hours. 
Extracellularly, there are two metabolites that have consistently lower levels in miR-429 
transfected cells. These metabolites are pyridoxine and glucarate. In the intracellular samples, 
there are two metabolites that have consistently lower levels in the miR-429 transfected cells as 
compared to the control transfected cells. These two metabolites are pyroglutamate and 6-
phosphogluconate. Recently, 6-phosphogluconate has been shown to inhibit EMT extracellularly 
through competitive inhibitory interactions with the cytokine glucose phosphate isomerase/AMF 
in breast cancer cells.17 No further studies were performed on intracellular levels of 6-
phosphogluconate, though, but since the levels of 6-phosphogluconate dropped during EMT, it is 
possible that intracellular levels are kept lower to avoid any possible membrane transportation to 
extracellular regions. Overall, these metabolites show that the cells are not metabolically the 
same as they initially were, suggesting some degree of metabolic hysteresis occurs during MET-
EMT.  
4.3. Conclusions 
Overall, there does not appear to be a system-wide metabolic perturbation caused by MET-EMT. 
Most large differences in metabolism were seen between time points, not between control and 
miR-429 transfected cells. This indicates that normal cellular growth and media depletion have a 
larger effect on cellular metabolism than the transfection of miR-429. Thus, a phenotypic change 
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large enough to detect morphologically did not affect the metabolome in a large way, perhaps 
contrary to expectation. This observation is particularly surprising and interesting in light of the 
other widespread changes observed during this phenotypic change in the protein, transcriptomic, 
and microRNA data. There do appear to be small changes during MET-EMT between control 
and miR-429 transfected cells though, suggesting a small hysteresis effect caused by the MET-
EMT. 
4.4. Methods 
4.4.1. MicroRNA Transfection 
The HEY cells were provided by Gordon Mills, Department of Molecular Therapeutics, 
University of Texas, MD Anderson Cancer Center. MicroRNA transfection of the HEY cells was 
based on the method developed in Chen, et al, 2011.16 HEY cells were seeded in a six well plate 
with a surface area of 6.9 cm2 at a density of 1x105 cells per well (1.45x104 cells/cm2) for the late 
time points and 3 x 105 cells per well (4.35x104 cells/cm2) for the early time points. After 24 
hours, the cells were transfected with 30 nM of miR-429 miRNA oligonucleotides (Ambion, 
Austin, TX) using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA). The Ambion Pre-
miRNA Precursor Negative Control was used as a control.  
4.4.2. Time Point Collection 
For the early time points, cells were harvested at 0, 3, 5, and 7 hours after microRNA 
transfection. For the late time points, cells were harvested at 24, 48, 72, and 144 hours. The 144 
hours samples were subcultured at 72 hours, reseeded at the original density, and then allowed to 
grow for another 72 hours at which point they were harvested as detailed below. 
4.4.3. Metabolite quenching and extraction 
Plates were removed from the incubator and media from each well was removed and snap frozen 
in liquid nitrogen for the extracellular samples. Cells were then quickly washed with 1mL PBS at 
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37°C, which was aspirated off, and then 700µL of 80:20 methanol/water solution at -80°C was 
added immediately. The plate was then incubated at -80°C for 15 minutes. After incubation, 
remaining cellular debris were harvested using a cell scraper (BD Falcon, San Jose, CA) for 
intracellular analysis. The intracellular solution was then transferred to a microcentrifuge tube in 
a cold ethanol bath and centrifuged at 5,000 g for 5 minutes at -4°C. The supernatant was 
retained, and the pellet was subsequently re-extracted twice in 100µL of the cold 80:20 
methanol/water solution, with all supernatants being pooled.18 Both intracellular and 
extracellular samples were stored at -80°C until analysis.  
4.4.4. Extracellular Sample Extraction 
Immediately before two dimensional gas chromatography-mass spectrometry (GCxGC-MS) 
analysis, an acetonitrile precipitation was performed on the extracellular samples to remove 
protein.19 Briefly, the extracellular samples were thawed on ice and 75µL was removed for 
GCxGC-MS analysis. 150µL of ice-cold acetonitrile was added to the sample, and the sample 
was vortexed for one minute. The sample was then centrifuged at 21,100 g for 7 minutes, and the 
supernatant removed for GCxGC-MS analysis. 
4.4.5. GCxGC-MS Analysis 
Before derivatization, both intracellular and extracellular samples were vacuum concentrated in a 
CentriVap at 40°C until completely dry. For the intracellular samples, a volume equated to 
7.5x104 cells for each sample was vacuum concentrated in order to achieve a concentration of 
3x104 cells/µL after derivatization. For the extracellular samples, the entire supernatant from the 
extracellular extraction was vacuum concentrated. The samples were derivatized using the 
protocol laid out by Fiehn, et. al as a basis.20 Briefly, 2.5µL of 40mg/mL O-
methylhydroxylamine hydrochloride (MP Biomedicals, LLC, Santa Ana, CA) in pyridine was 
added to the dried sample and shaken at 1400 rpm for 90 minutes at 30°C. 22.5µL of N-methyl-
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N-(trimethylsilyl) trifluoroacetamide (MSTFA) + 1% trimethylchlorosilane (TMCS) (Thermo 
Scientific, Lafayette, CO) was then added to the samples which were then shaken at 1400 rpm 
for 30 minutes at 37°C. Samples were centrifuged at 21,100 g for 3 minutes and 15µL of the 
supernatant was added to an autosampler vial. Samples were spiked with 0.10µL of a retention 
time standard solution consisting of fatty acid methyl esters (FAMEs) and an internal standard of 
nonadecanoic acid methyl ester dissolved in dimethylformamide. 
A LECO Pegasus 4D instrument with an Aglient 7683B autosampler, Agilent 7890A gas 
chromatograph and time-of-flight mass spectrometer (TOF-MS) was used to analyze the 
samples. The first column was an HP-5, 30m late x 0.320mm ID x 0.25µm film thickness 
(Agilent, Santa Clara, CA), and the second was an Rtx-200, 2m late x 0.25mm ID x 0.25µm film 
thickness (Restek, Bellefonte, PA). Specific autosampler, gas chromatography, and mass 
spectrometry methods can be found in Appendix A. 
4.4.6. Data Analysis 
Sample runs were first analyzed in ChromaTOF (LECO, St. Joseph, MI) to determine baseline, 
peak area, and peak identification. Briefly, settings included a baseline offset of 0.5, automatic 
smoothing, 1st dimension peak width of 21 seconds for intracellular and 12 seconds for 
extracellular, 2nd dimension peak width of 0.10 seconds, and a match of 700 required to combine 
peaks with a minimum signal-to-noise (S/N) of 5 for all subpeaks. Peaks were required to have a 
S/N of 10 and have a minimum similarity score of 800 before assigning a name. Unique mass 
was used for area and height calculation.  
To align the samples, MetPP (http://metaopen.sourceforge.net/metpp.html) was used.21 Sample 
files and a derivatization reagent blank file were uploaded from ChromaTOF. Unknowns were 
retained during the peak alignment process. The derivatization reagent blank file was used to 
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subtract peaks attributable only to derivatization reagents from the sample files. On-the-fly 
alignment was used with quality control samples manually selected as the peak list for primary 
alignment. Peak alignment was performed using the default criteria. 
After alignment, further processing of the data was done using an in-house written MATLAB 
program. Quality control samples were used to remove analytes that were inconsistently 
measured. If more than half of the values for a given analyte were missing in the quality control 
samples or if the quality control samples had a coefficient of variance larger than 0.5 excluding 
missing values, the entire analyte was removed. Then, missing values were manually corrected 
using small value correction if all the values were missing in the biological replicate. 
Finally, MetaboAnalyst (http://metaboanalyst.ca/) was used for statistical and enrichment 
analysis, applying both the statistical analysis and time series analysis modules.22 Once the data 
was uploaded, remaining missing values were k-nearest neighbors (KNN) corrected. Data was 
filtered using the interquantile range method and then log-transformed using generalized 
logarithm transformation (base 2) and autoscaled. Analysis was performed using both unknown 
and annotated analytes together and annotated analytes only. 
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Chapter 5 Conclusions and recommendations for future work 
5.1. Conclusions 
The work done in this thesis explored the differences in metabolism between ovarian cancer stem 
cells (OCSCs) and ovarian cancer cells (OCCs) through three separate avenues: (1) by defining 
the baseline metabolic differences between the two cell types, (2) by determining the differences 
between OCCs and OCSCs in their metabolic response to biologically based perturbations, and 
(3) by profiling the metabolic changes that occurred during the mesenchymal to epithelial 
transition (MET) and epithelial to mesenchymal transition (EMT). This is the first metabolomics 
study that characterizes the differences between an isogenic ovarian cancer cell line and ovarian 
cancer stem cell line. To date, there are only a handful of papers addressing cancer stem cell 
metabolism in any way and only one other paper studying metabolic differences on a systems-
scale. Characterization of the metabolic differences between cancer cells and cancer stem cells 
provides us a greater understanding of how metabolic dynamics are altered and, once identified, 
may help us the ability to utilize these alterations for targeted treatment. 
5.1.1. OVCAR-3-derived ovarian cancer stem cells display distinct metabolic 
profiles 
Previous gene expression analysis of OCSCs and OCCs identified several metabolic pathways 
that were significantly enriched in differentially expressed genes. However, the relationship of 
enzyme expression to metabolic phenotype is complex and does not imply a direct one-to-one 
correlation. To determine if there were substantial metabolic changes corresponding with these 
transcriptional differences, two-dimensional gas chromatography coupled to mass spectrometry 
was used to measure the metabolite profiles of the OCCs and OCSCs. These two cell lines 
exhibited significant metabolic differences in intracellular metabolite measurements. Pathway 
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analysis of intracellular metabolomics data revealed close overlap with metabolic pathways 
identified from gene expression data, with four out of six pathways found to be enriched in gene-
level analysis also enriched in metabolite-level analysis. One of the most significantly enriched 
pathways, arginine and proline metabolism, contained six metabolites that are each statistically 
significantly different between the two cells. Two of those metabolites, proline and putrescine, 
have been previously implicated in cancer, but the changes displayed between normal and cancer 
cells were discordant with the changes they displayed between the OCCs and OCSCs.  
Lower levels of proline and putrescine in OSCSs may be explained in the context of current 
research in stem cell metabolism, where proline has been shown to cause differentiation and 
putrescine was found to have different levels in mESCs and induced pluripotent stem cells 
(iPSCs). These findings suggest that OCSCs may exist in a metabolic balance between potency 
and proliferation. This is noteworthy because OCSCs are thought to be transient (OCSCs may 
switch to OCCs and vice versa) and as the cancer cells become more stem-like, their metabolism 
must transition from supporting a highly proliferative phenotype to supporting a higher potency 
phenotype. Therefore, metabolism may play a larger role in retaining stemness than heretofore 
believed and further research into stem cell and cancer stem cell metabolism may reveal other 
metabolites that support stemness. Overall, metabolism in this OCSC line is distinct from that of 
more differentiated isogenic cancer cells, showing similarities to stem cell metabolism that 
suggest the potential importance of metabolism for the cancer stem cell phenotype. 
5.1.2. Metabolic perturbations of OCCs and OCSCs 
Chemotherapeutic, glucose deprivation, hypoxia, and ischemia perturbations were applied to 
OCCs and OCSCs grown in vitro to profile the heterogeneous metabolic profiles that would be 
expected in a tumor. Docetaxel was selected as the chemotherapeutic used for this experiment, 
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and it caused metabolic changes mostly within amino acid and carbohydrate metabolism in 
OCCs but did not affect OCSC metabolism. Docetaxel also increased the levels of uracil within 
the OCCs, which may be indicative of increased cellular dependence on uracil under docetaxel 
treatment. If this were the case, it would help to explain why treating tumors with docetaxel and 
a competitive inhibitor of uracil was shown to improve treatment results over treatment with 
docetaxel only.  
Glucose deprivation, hypoxia, and ischemia all perturbed OCC and OCSC metabolism, but not 
equally. Hypoxia had a much larger effect on OCC metabolism, while glucose deprivation had a 
greater effect on OCSC metabolism. OCSCs may not respond to hypoxic conditions because 
they are normally found within a hypoxic niche in the tumor and therefore, their metabolism 
might be adapted to a hypoxic environment. The different responses to glucose deprivation 
suggests that OCSCs are much more dependent on glucose than OCCs, which may indicate that 
OCSCs utilize glucose differently than OCCs. Cancer cells have adapted different pathways for 
supplying their energy requirements, such as glutaminolysis, which can help negate glucose 
deprivation. These pathways may be lacking in OCSCs or OCSCs may use glucose for anabolic 
pathways that OCCs do not, which could explain the widespread alterations in OCSC 
metabolism during glucose deprivation. Ischemia perturbed metabolism in both of the cell types 
in many of the same pathways, suggesting that OCCs and OCSCs respond to this stress similarly. 
Both cells had metabolic pathways statistically significantly enriched under ischemia that did not 
appear in hypoxia for OCCs or in glucose deprivation for OCSCs, suggesting that ischemia is not 
simply an additive affect of hypoxia and glucose deprivation.  
Even though OCCs and OCSCs responded differently to the three metabolic perturbations, there 
were a few metabolites that were altered in all of the conditions for both cell types. One of these 
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metabolites, phosphoethanolamine, showed a similar increasing trend in response to all the 
perturbations for both cell types, suggesting the phosphoethanolamine may just be responding to 
the stress the cells are under and not the specific perturbation. Recent research has also shown 
that phosphoethanolamine can induce apoptosis in cancer cells, suggesting some possible 
interaction between these stress and apoptotic pathways potentially metabolic in nature. 
Therefore, OCSCs and OCCs may be increasing phosphoethanolamine levels to induce apoptosis 
in response to the stress the cells are undergoing.  
5.1.3. Metabolic changes during mesenchymal to epithelial transition 
System-wide metabolic changes were not detected during MET-EMT in HEY cells. Instead, 
most of the metabolic differences were temporal, suggesting that normal cellular growth and 
media depletion have a larger effect on the cellular metabolism than miR-429 induced MET-
EMT. A small number of metabolic differences were detected between control and miR-429 
transfected cells while shifting back from epithelial to mesenchymal phenotype, which hints at a 
possible hysteresis effect caused by the MET-EMT. Overall, the lack of system-wide metabolite 
changes was contrary to expectation since miR-429 induced MET-EMT caused a phenotypic 
change large enough to detect morphologically and was observed in the protein, transcriptomic, 
and microRNA data collected alongside the metabolomics data. The differences noticed during 
MET-EMT in the other data may affect areas of metabolism (such as lipid metabolism) are not 
captured well by the techniques used in this study.  
5.2. Relevance of thesis work 
Altered metabolism has recently been identified as a hallmark of cancer. Many of the common 
oncogenes (such as HIF, PI3K, Myc, and p53) have been shown to alter metabolism, as well as 
mutations of key metabolic enzymes. Most of these discoveries have been made through studies 
of individual enzymes or pathways, but recently, metabolomics has begun to be used for 
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characterization of cancer metabolism, biomarker and diagnostic discovery, staging of cancer, 
and pharmacometabolomics. One area of cancer research that before this thesis had not been 
explored is characterization of the differences between cancer cell and cancer stem cell 
metabolism.  
The work in this thesis used metabolomics to explore the metabolic differences between isogenic 
ovarian cancer and cancer stem cell lines. The baseline characterization and chemotherapeutic 
and environmental perturbations experiments had not been performed before with isogenic 
cancer cell and cancer stem cell lines. The experimental setup can be used for any isogenic 
cancer and cancer stem cell lines to expand cancer stem cell characterization into other cancer 
types. Besides the isogenic pair characterization, profiling the metabolic changes induced during 
mesenchymal-to-epithelial and epithelial-to-mesenchymal had never been reported before, even 
if no large-scale metabolic changes were detected. Moving forward, this same experimental 
design could be applied toward studying different areas of the metabolome during EMT and 
MET that were not captured here (such as lipids). 
The novel findings of this thesis suggest a number of conclusions and future directions that 
would not have been possible without this work. First, it showed that there can be substantial 
metabolic differences between otherwise isogenic cells both in continuous culture propagation 
and in response to environmental challenges. Furthermore, some of the metabolic differences 
may result directly from the stemness of the cells, drawing the relationship between cancer stem 
cells and cancer cells closer to that of normal cells and stem cells (though this hypothesis still 
needs further validation as described in section 5.3.1). It was also found that OCSCs do not 
respond metabolically to docetaxel, suggesting that OCSCs are fully resistant to docetaxel. Also, 
OCSCs did not experience a metabolic shift while under hypoxic conditions, yet did during 
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glucose deprivation, suggesting that OCSCs have metabolically adapted to hypoxic conditions 
yet still depend on glucose for their altered metabolism despite their slow rate of proliferation.  
Overall, the work in this thesis starts to fill in large gaps in the current knowledge of ovarian 
cancer stem cell metabolism and lays a foundation for continuing characterization of other 
cancer stem cell types. Importantly, the information and insight gleaned from this work can be 
used in the development of future therapeutics or treatment combinations to specifically target 
cancer stem cells, a putatively important cause of cancer recurrence and mortality, via 
metabolism. 
5.3. Recommendations for future work 
Moving forward, the next immediate steps for this project should involve validation experiments 
for further support of the hypothesis that differences in proline and putrescine levels between 
OCCs and OCSCs are directly related to the stemness of the cell. These experiments are 
described in section 5.3.1. After the validation experiments, the next experiments should involve 
expansion of the biologically based perturbations, especially for chemotherapeutics, as detailed 
in section 5.3.2. The metabolic response to different chemotherapeutics, such as treatments 
targeted toward the OCSCs, may reveal increased cellular dependence on certain pathways or 
metabolites, which could provide further targeted treatments to be supplied in conjunction with 
the chemotherapeutic. Finally, these experiments should be expanded to other cancer stem cell 
lines, as described in section 5.3.4, to determine if the results shown here are specific to the 
OCCs and OCSCs profiled or if they apply to cancer stem cells in general. Because cancer stem 
cell lines are not easily obtained, another option for expansion would be to mimic the tumor 
stroma in vitro with the OCCs and OCSCs and profile the metabolic responses of the cells in 
response to the biologically based perturbations already tested to determine the effect tumor 
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stroma interactions have on cellular metabolism. These experiments are described in greater 
detail in section 5.3.3. 
5.3.1. Proline and putrescine validation experiments 
During characterization of the baseline differences of OCSCs and OCCs, proline and putrescine 
were found to be key metabolites that might help explain the differences in metabolism between 
the two cells types in terms of the cell stemness. To support these findings, further validation 
studies should be performed to determine if the lower levels of proline and putrescine found in 
OCSCs do indeed help these cells retain their stem like state. 
5.3.1.1. Gene knockdown 
One such study would involve the knockdown, silencing, or inhibition of key enzymes used to 
metabolize proline and putrescine in OCCs to determine if these cells would then shift toward a 
more stem like state. For proline, proline oxidase (POX), which catalyzes the oxidation of 
proline to pyrroline-5-carboxylate (P5C), should be inhibited as it has been shown previously 
that the production of P5C from proline causes differentiation of mouse embryonic stem cells 
(mESCs).1 POX was also found to be down-regulated in OCSCs as compared to OCCs during 
gene expression analysis. Therefore, inhibition of POX would drastically reduce the production 
of P5C, which might shift the OCCs towards a more stem-like state. For putrescine, no singular 
enzymatic reaction has been linked to the ability of putrescine to cause differentiation, so 
different enzymes that produce putrescine should be tested. N1-acetylpolyamine oxidase 
(APAO), which catalyzes the breakdown of spermidine to putrescine in the polyamine 
catabolism pathway, would be one possible choice for knockdown as the polyamine catabolism 
pathway is known to be dysregulated in cancer. After inhibition or knockdown, expression of 
CD44 can be used to determine if the OCCs have become more stem-like, as OCSCs have been 
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shown to have higher expression of CD44 than OCCs.2 Measurement of CD44 expression can be 
performed using flow cytometry. Phenotypic changes might also occur and indicate a shift 
toward OCSCs.  
5.3.1.2. Metabolic flux analysis 
Another experiment that can be performed to validate our findings regarding proline and 
putrescine would be to use metabolic flux analysis to profile the arginine and proline metabolism 
pathway. Profiling the flux for the OCCs and OCSCs will allow us to determine how the flow of 
metabolites through the arginine and proline metabolism pathway differs; for instance, if the 
metabolic flux is shunted off to avoid certain reactions (such as proline oxidation to P5C) for the 
OCSCs. The results from these experiments will not directly tie the levels of proline and 
putrescine to differentiation, but will further support that the arginine and proline metabolism 
pathway is utilized differently in the two cells.  
5.3.2. Other biological perturbations 
In this work, glucose deprivation, hypoxia, ischemia, and a chemotherapeutic treatment were 
applied as biologically-inspired perturbations to bring the in vitro environment closer to the in 
vivo tumor microenvironment and to determine the differences between OCCs and OCSCs in 
their response to these perturbations. Besides these four, other biologically-inspired perturbations 
can also be applied to this system to gain further insight into tumor metabolism. Lactic acid 
production is elevated in cancers cells due to the increased flux through glycolysis.3 The lactic 
acid and CO2 (generated by the PPP) produced by the cancer cells is enough to lower the 
extracellular pH from 7.4 (physiological pH) to below 6.5 in some tumor locations.4 This acidic 
environment helps cancer cells to decrease sensitivity to hypoxia, stimulate metastasis, and 
increase drug resistance.5, 6 Pilot experiments performed during this thesis work showed that 
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lowering media pH alone had no effect, but it would be interesting to combine a lowered media 
pH with hypoxia or a chemotherapeutic treatment to determine if the metabolism of the OCCs or 
OCSCs respond differently than when they subjected to hypoxia and chemotherapy only.  
Another perturbation that might have effect on cancer cellular metabolism is estrogen. Estrogen, 
a steroid hormone, has been found to alter OCC proliferation. 17β-estradiol (E2) has been shown 
to promote cell proliferation in OVCAR-3 cells.7 It has also been found that 4-hydroxy E2 (4-
OHE2) can induce OVCAR-3 expression of HIF-1α.8 To determine the metabolic response of 
the OCCs and OCSCs, estrogen would be supplied to the cells at varying physiological levels. 
As estrogen induces the expression of HIF-1α, OCCs and OCSCs might exhibit metabolic 
profiles similar to those from the hypoxia studies. 
As stated in Chapter 3, ovarian cancer is commonly treated with a platinum compound and a 
taxane compound. Docetaxel, a taxane, was chosen as the initial chemotherapeutic treatment for 
the metabolic perturbation experiment due to the fact that it interrupts cellular division and thus 
would likely have an effect on cellular metabolism. Other chemotherapeutics should be explored 
in order to determine the metabolic responses to different chemotherapies, especially those with 
different method of actions. For example, cisplatin, a platinum compound and one of the most 
frequently used first line treatments against ovarian cancer, reacts with DNA to form DNA 
adducts that trigger signal transduction pathways which can evidently lead to apoptosis.9 Since 
docetaxel and cisplatin have differing methods of action, it is expected that the cellular 
metabolism response would differ as well. Another interesting chemotherapeutic option would 
be to use one that is targeted toward cancer stem cells. Since chemotherapeutics targeted toward 




5.3.3. Profile metabolism of OCICs and OCCs in response to stroma 
The environment surrounding the tumor (its microenvironment) lends important stimulatory 
biological signaling to the tumor. Through these interactions, the tumor is able to expand and 
resist interferences from the body (e.g., the immune system) or outside sources (e.g., 
chemotherapy). Stroma lends greater drug resistance to the tumor cells they surround; therefore, 
tumor-stroma interaction pathways are emerging as possible therapeutic targets.10 Because of the 
drug resistance that the stroma interactions give to the tumor, high-throughput screening methods 
are being developed to identify chemotherapeutics with increased activity against stroma cells.11 
In order to better understand how these interactions may impact metabolism, the tumor 
microenvironment can be simulated in vitro to determine how tumor-stroma interactions affect 
the OCCs’ and OCSCs’ response to environmental perturbations. 
The results of this study would identify whether interactions between the stroma and CCs cause 
metabolic changes that help to sustain the tumor under applied stress. Metabolic pathways that 
undergo regulation from the tumor-stroma signaling could be identified by comparison to the 
data from the OCCs or OCSCs only. With this information, potential inhibitors or activators of 
the metabolic pathways involved in the tumor-stroma interactions could be identified and used as 
therapeutics to make the tumor more sensitive to other treatments. 
5.3.4. Explore metabolism differences using different cell lines for ovarian 
cancer and expand into other cancers 
Besides the isogenic system used for the studies in this work, there exist a few other isolated 
cancer stem cells in ovarian cancer and other cancers.12-15 Extending this same study into other 
cancer stem cells would help to determine if the results found here are specific to this cell 
system, to ovarian cancer, or to cancer stem cells in general. The drawback to this extension is 
that these other isolated cancer stem cells are difficult to obtain. They are not available through 
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traditional means (such as ATCC) and would only be obtainable through direct contact with the 
group that isolated the cancer stem cells. Hopefully, as the research into cancer stem cells 
continues, these cells will be more easily obtainable which would allow the continuation of this 
research. 
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An Agilent 7683 autosampler was used. Three pre-washes with pyridine were performed before 
each injection. The sample was then pumped into the syringe 4 times. The syringe size was 10µL 
with a sample volume of 1µL injected into the inlet. Three post-washes with pyridine were 
performed after injection. 
GC Method 
An Agilent 7890 gas chromatograph adapted to GCxGC analysis was used. The first column was 
an HP-5, 30m long x 0.320mm ID x 0.25µm film thickness (Agilent, Santa Clara, CA), and the 
second was an Rtx-200, 2m long x 0.25mm ID x 0.25µm film thickness (Restek, Bellefonte, 
PA). The excluded masses in auto mass defect mode option was chosen. Helium was used as the 
carrier gas with a corrected constant flowrate of 1.00mL/min. An inlet septum purge flow of 
3mL/min was chosen. The inlet was operated in splitless mode with a purge flow of 100mL/min 
set to start 30 seconds after injection, yielding a total flow of 101mL/min. Gas saver mode was 
used, with a flow of 20mL/min set to start a minute after injection. 
Table A1: Main Oven Temperature Program for Intracellular and Extracellular Samples 
Rate (°C/min) Target Temp (°C) Duration (min) 
Initial 70 1 
10 315 2 
 
The main oven temperature program can be found in Table A1. The secondary oven temperature 
offset was 5°C and the modulator temperature offset was 20°C from the main oven. An 
equilibration time of 60 seconds was set for the ovens. The modulation timing is listed in Table 




Table A2: Modulation Timing 
# Start (s) End (s) Modulation Period (s) Hot Pulse Time (s) Cold Pulse Time (s) 
Intracellular Samples 
1 Start 575 5.00 1.00 1.50 
2 575 797 6.00 1.50 1.50 
3 797 End 4.00 1.50 0.50 
Extracellular Samples 
1 Start 492 4.00 0.50 1.50 
2 492 747 5.00 1.00 1.50 
3 747 1099 4.00 1.00 1.00 
4 1099 End 4.00 1.50 0.50 
 
MS Method 
A LECO Pegasus IV D time of flight mass spectrum (TOF-MS) was used. The total MS method 
time was based on the GC method time. The acquisition delay was set to 240 seconds, with the 
filaments being turned off until then. The collection mass range was from 50 to 500u. The 
acquisition rate was set to 200 spectra/second. The detector voltage was set to 100V above the 
optimized voltage with the electron energy set to -70V. The mass defect mode was set to manual 
with the mass defect 0mu/ 100u. The ion source temperature was 220°C and the run had to wait 
for the ion source temperatures to reach the set point before starting acquisition. 
 
